Pills

This is the text extract for Schedule Update - effective 1 December 2013, browse documents here.


Pharmaceutical Management Agency

Update

New Zealand Pharmaceutical Schedule

Effective 1 December 2013

Cumulative for September, October, November and December 2013


Contents

Summary of PHARMAC decisions effective 1 December 2013 ....................... 3 Antibiotics for the Rheumatic Fever Prevention Programme (RFPP) ............... 5 Montelukast access widened ....................................................................... 5 Benzbromarone prescribing information....................................................... 6 Haemophilia treatments ................................................................................ 6 Brand name change for Mylan olanzapine and spironolactone ..................... 6 Gabapentin – new listing .............................................................................. 6 Pramipexole – new listing of Ramipex brand ................................................. 7 Carbimazole – stock shortage ....................................................................... 7 Tender transitions for ropinirole hydrochoride extended ............................... 7 News in brief ................................................................................................. 7 Tender News .................................................................................................. 8 Looking Forward ........................................................................................... 8 Sole Subsidised Supply products cumulative to December 2013 ................... 9 New Listings ................................................................................................ 20 Changes to Restrictions, Chemical Names and Presentations ...................... 26 Changes to Subsidy and Manufacturer’s Price............................................. 35 Changes to General Rules............................................................................ 38 Changes to Brand Name ............................................................................. 41 Changes to Section I ................................................................................... 43 Delisted Items ............................................................................................. 44 Items to be Delisted .................................................................................... 47 Index ........................................................................................................... 50

2


Summary of PHARMAC decisions

EFFECTIVE 1 DECEMBER 2013 New listings (pages 20-21) • Mesalazine (Pentasa) suppos 1 g • Eptacog alfa [Recombinant Factor VIIA] [Xpharm] (NovoSeven RT) inj 1 mg syringe, 2 mg syringe, 5 mg syringe and 8 mg syringe • Moroctocog alfa [Recombinant Factor VIII] [Xpharm] (Xyntha) inj 250 iu vial, 500 iu vial, 1,000 iu vial, 2,000 iu vial and 3,000 iu vial • Nonacog alfa [Recombinant Factor IX] [Xpharm] (BeneFIX) inj 250 iu vial, 500 iu vial, 1,000 iu vial and 2,000 iu vial • Octocog alfa [Recombinant Factor VIII] [Xpharm] (Advate) inj 250 iu vial, 500 iu vial, 1,000 iu vial, 1,500 iu vial, 2,000 iu vial and 3,000 iu vial • Octocog alfa [Recombinant Factor VIII] [Xpharm] (Kogenate FS) inj 250 iu vial, 500 iu vial, 1,000 iu vial, 2,000 iu vial and 3,000 iu vial • Factor eight inhibitors bypassing agent [Xpharm] (FEIBA) inj 500 U and 1,000 U • Compound electrolytes (Enerlyte) powder for oral soln • Spironolactone (Spiractin) tab 25 mg and 100 mg • Urea (healthE Urea Cream) crm 10 %, 100 g OP • Oxytocin (Oxytocin BNM) inj 5 iu per ml, 1 ml ampoule and 10 iu per ml, 1 ml ampoule • Lamivudine (Lamivudine Alphapharm) tab 150 mg • Ropinirole hydrochloride (Apo-Ropinirole) tab 0.25 mg, 1 mg, 2 mg and 5 mg • Pramipexole hydrochloride (Ramipex) tab 0.25 mg and tab 1 mg – S29 • Gabapentin (Arrow-Gabapentin) cap 100 mg, 300 mg, 400 mg • Olanzapine (Zypine) tab 2.5 mg, 5 mg and 10 mg • Olanzapine (Zypine ODT) tab orodispersible 5 mg and 10 mg Changes to restrictions, chemical names and presentation (pages 26-29) • Compound electrolytes – amendment to presentation description • Enalapril maleate – removal of brand switch fee • Cetomacrogol with glycerol – amendment to units of measure • Oxytocin - amendment to presentation description • Carbimazole – removal of STAT • Erythromycin ethyl succinate (E-Mycin) tab 400 mg and grans for oral liq 200 mg per 5 ml – amendment to PSO quantities and addition of RFPP • Amoxycillin (Alphamox and Ospamox) cap 250 mg, 500 mg and grans for oral liq 250 mg per 5 ml - amendment to PSO quantities and addition of RFPP

3


Summary of PHARMAC decisions – effective 1 December 2013 (continued) • Phenoxymethylpenicillin (penicillin V) (Cilicaine VK and AFT) cap potassium salt 500 mg and grans for oral liq 250 mg per 5 ml - amendment to PSO quantities and addition of RFPP • Benzbromarone (Benzbromarone AL 100) tab 100 mg - addition of note • Ropinirole hydrochloride – removal of certified exemption • Naltrexone hydrochloride – amendment of Special Authority • Montelukast – amendment of Special Authority Decreased subsidy (page 35) • Clopidogrel (Apo-Clopidogrel) tab 75 mg • Tamsulosin hydrochloride (Tamulosin-Rex) cap 400 mcg, 30 cap packsize • Morphine sulphate (m-Eslon) cap long-acting 10 mg, 30 mg, 60 mg and 100 mg • Loratadine (Loraclear Hayfever Relief) tab 10 mg

4


Pharmaceutical Schedule - Update News

5

Antibiotics for the Rheumatic Fever Prevention Programme (RFPP)

From 1 December 2013 the provisions relating to the subsidy of Practitioner Supply Orders (PSO) will change to include PSOs for the Rheumatic Fever Prevention Programme (RFPP). Please refer to the insert provided with this Update for further information. PSOs for the Rheumatic Fever Prevention Programme • A Practitioner may order up to 10 X the maximum amount normally allowed for amoxycillin in course-specific amounts. • A Practitioner may order up to 2 X the maximum amount normally allowed for phenoxymethyl penicillin and erythromycin in course-specific amounts. • The pharmacy will dispense each course separately in accordance with the Ministry of Health guidelines. • The pharmacy will claim service fees for each dispensing as per the Community Pharmacy Services Agreement. Annotation of PSOs for the Rheumatic Fever Prevention Programme • The name of the RFPP provider must be written on the PSO • The order quantity must be specified in course-specific amounts on the PSO There will be additional antibiotics added to the PSO list (Section E Part I) and changes to the maximum quantity of some antibiotics already on the PSO list, for details refer to page 26 of this Update.

Montelukast access widened

The Special Authority criteria for montelukast will be amended from 1 December 2013. The criteria relating to pre-school wheeze and exercise induced asthma will be widened and clarified so that prescribers can more easily access funded treatment for their patients.


6

Pharmaceutical Schedule - Update News

Benzbromarone prescribing information

Benzbromarone (Benzbromaron AL 100) is funded, subject to Special Authority criteria, as a last-line treatment for gout. It is not registered with Medsafe in New Zealand so must be prescribed and supplied in accordance with section 25 and section 29, respectively, of the Medicines Act 1981. We have been advised by the New Zealand Rheumatology Association that it has developed prescribing information for benzbromarone, which it has made available on its website at http://www.rheumatology.org.nz/ benzbromarone_prescriber_information.cfm We have included a link to this information on the benzbromarone Special Authority form and in the HML restrictions.

Haemophilia treatments

From 1 December 2013, a number of haemophilia treatments (recombinant blood factors (VIIa, VIII and IX) and factor eight inhibitors bypassing agent (FEIBA)) will be listed. The products will be listed XPharm and will continue to be managed by the National Haemophilia Management Group and distributed via the existing processes.

Brand name change for Mylan olanzapine and spironolactone

Mylan is changing the brand name of its olanzapine from Olanzine and Olanzine D to Zypine and Zypine ODT. Mylan is also changing the brand name of its spironolactone from Spirotone to Spiractin. The new brands, with new Pharmacodes, will be listed from 1 December 2013. Olanzine, Olanzine-D and Spirotone will be delisted at a later date.

Gabapentin – new listing

The Arrow-Gabapentin brand of gabapentin 100 mg, 300 mg and 400 mg capsules will be listed from 1 December 2013 subject to the same Special Authority Criteria that currently apply to the Nupentin brand. The Nupentin brand of gabapentin cap 300 mg and 400 mg will have a subsidy reduction from 1 March 2014. From 1 March 2014, the Nupentin brand will be fully funded for patients with a Special Authority for epilepsy prior to March 2014, via a higher subsidy by endorsement.


Pharmaceutical Schedule - Update News

7

Pramipexole – new listing of Ramipex brand

The Ramipex brand of pramipexole 0.25 mg and 1 mg tablets will be listed fully funded from 1 December 2013. Ramipex is an unapproved medicine so must be prescribed and supplied in accordance with section 25 and section 29, respectively, of the Medicines Act 1981.

Carbimazole – stock shortage

AFT have notified that there may be a shortage of Neo- Mercazole, (carbimazole). AFT currently still have stock and expect new stock to arrive in January 2014. Due to this potential shortage ‘stat dispensing’ will be removed from carbimazole 5 mg tablet from 1 December 2013 until further notice. Patients may need to see their prescriber if stock is unavailable.

Tender transitions for ropinirole hydrochoride extended

Apo-Ropinirole (ropinirole) tab 0.25 mg, 1 mg, 2 mg and 5 mg, supplied by Apotex NZ Ltd, will be listed from 1 December 2013 as previously notified, however Apotex do not expect to have stock available until mid-December. We are listing this product from the first of the month, so product will be subsidised as soon as it's available. The tender transition dates relating to the reference pricing and delisting of the Mylan brand (Ropin) have been delayed by one month with reference pricing on 1 March 2014 and delisting on 1 June 2014. Due to the potential for a shortage of stock the certified exemption on ropinirole will be removed from 1 December 2013 until Apotex are able to supply.

News in brief

• Moducal (carbohydrate supplement powder) will be delisted from 1 June 2014. • Novofine 31G x 6 mm pen needles will be delisted from 1 June 2014. • Combivir (zidovudine 300 mg with lamivudine 150 mg tablets) will be delisted from 1 June 2014. The Alphapharm brand of zidovudine [AZT] with lamivudine will remain subsidised. • Zofran Zydis (ondansetron 4 mg dispersible tablets) will be delisted from 1 March 2014. Dr Reddy’s brand of ondansetron 4 mg dispersible tablets is back in stock.


Tender News

Sole Subsidised Supply changes – effective 1 January 2014

Chemical Name Ascorbic acid Cefaclor monohydrate Cefaclor monohydrate Clotrimazole Clotrimazole Hyoscine hydrobromide Oxycodone hydrochloride Oxycodone hydrochloride Oxycodone hydrochloride Oxycodone hydrochloride Vitamin B complex Vitamins Presentation; Pack size Tab 100 mg; 500 tab Cap 250 mg; 100 cap Grans for oral liq 125 mg per 5 ml; 100 ml Vaginal crm 1% with applicators; 35 g OP Vaginal crm 2% with applicators; 20 g OP Patch 1.5 mg; 2 patch Tab controlled-release 10 mg; 20 tab Tab controlled-release 20 mg; 20 tab Tab controlled-release 40 mg; 20 tab Tab controlled-release 80 mg; 20 tab Tab, strong, BPC: 500 tab Tab (BCP cap strength); 500 tab Sole Subsidised Supply brand (and supplier) Cvite (Boucher) Ranbaxy-Cefaclor (Douglas) Ranbaxy-Cefaclor (Douglas) Clomazol (Multichem) Clomazol (Multichem) Scopoderm TTS (Novartis) Oxydone BNM (InterPharma) Oxydone BNM (InterPharma) Oxydone BNM (InterPharma) Oxydone BNM (InterPharma) Bplex (Boucher) Mvite (Boucher)

Looking Forward

This section is designed to alert both pharmacists and prescribers to possible future changes to the Pharmaceutical Schedule. It may also assist pharmacists, distributors and wholesalers to manage stock levels. Possible decisions for future implementation 1 January 2014 • Eltrombopag (Revolade) tab 25 mg and 50 mg – Special Authority – new listing • Erlotinib hydrochloride (Tarceva) tab 100 mg and 150 mg reduction in price and subsidy and widening of Special Authority. • Ethinyloestradiol with levonorgestrel, tab 20 mcg with levonorgestrel 100 mcg and 7 inert tab (Ava 20 ED) and tab 30 mcg with levonorgestrel 150 mcg and 7 inert tab (Ava 30 ED) price and subsidy reduction. • Fluticasone with salmeterol (Seretide, Seretide Accuhaler) – removal of Special Authority

8


Sole Subsidised Supply Products – cumulative to December 2013

Generic Name

Abacavir sulphate Acarbose Acetazolamide Acetylcysteine Aciclovir Allopurinol Amantadine hydrochloride Aminophylline Amiodarone hydrochloride Amisulpride Amitriptyline Amlodipine Amoxycillin Amoxycillin clavulanate

Presentation

Oral liq 20 mg per ml Tab 300 mg Tab 50 mg and 100 mg Tab 250 mg Inj 200 mg per ml, 10 ml Tab dispersible 200 mg, 400 mg & 800 mg Tab 100 mg & 300 mg Cap 100 mg Inj 25 mg per ml, 10 ml Inj 50 mg per ml, 3 ml ampoule Oral liq 100 mg per ml Tab 100 mg, 200 mg & 400 mg Tab 10 mg Tab 25 mg & 50 mg Tab 2.5 mg Tab 5 mg & 10 mg Inj 250 mg, 500 mg & 1 g Grans for oral liq amoxycillin 125 mg with potassium clavulanate 31.25 mg per 5 ml Grans for oral liq amoxycillin 250 mg with potassium clavulanate 62.5 mg per 5 ml Tab 500 mg with potassium clavulanate 125 mg Crm Tab 50 mg & 100 mg Tab 10 mg, 20 mg, 40 mg & 80 mg Inj 600 mcg, 1 ml Tab 500 mg Tab 10 mg Tab 2.5 mg & 5 mg Inj 1.2 mega u per 2.3 ml Inj 600 mg Eye drops 0.5% Eye drops 0.25%

Brand Name Expiry Date*

Ziagen Ziagen Accarb Diamox Martindale Acetylcysteine Lovir Apo-Allopurinol Symmetrel DBL Aminophylline Cordarone-X Solian Arrow-Amitriptyline Amitrip Apo-Amlodipine Apo-Amlodipine Ibiamox Augmentin Augmentin Curam Duo AFT Mylan Atenolol Zarator AstraZeneca Apo-Azithromycin Pacifen ArrowBendrofluazide Bicillin LA Sandoz Betoptic Betoptic S 2014 2014 2015 2015 2015 2015 2016 2014 2015 2014 2014 2014 2015 2014 2015 2016 2014 2014 2014 2016 2016 2014 2014 2014 2015

Aqueous cream Atenolol Atorvastatin Atropine sulphate Azithromycin Baclofen Bendrofluazide Benzathine benzylpenicillin Benzylpenicillin sodium (Penicillin G) Betaxolol hydrochloride

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

9


Sole Subsidised Supply Products – cumulative to December 2013

Generic Name

Bezafibrate Bicalutamide Blood glucose diagnostic test meter Blood glucose diagnostic test strip Boceprevir Brimonidine tartrate Bupropion hydrochloride Cabergoline Calamine Calcitonin Calcium carbonate Calcium folinate Candesartan Carbomer Cefalexin monohydrate

Presentation

Tab 200 mg Tab long-acting 400 mg Tab 50 mg Meter with 50 lancets, a lancing device and 10 diagnostic test strips Blood glucose test strips Cap 200 mg Eye drops 0.2% Tab modified-release 150 mg Tab 0.5 mg Lotn, BP Inj 100 iu per ml, 1 ml Tab 1.25 g (500 mg elemental) Tab eff 1.75 g (1 g elemental) Tab 15 mg Tab 4 mg, 8 mg, 16 mg & 32 mg Ophthalmic gel 0.3%, 0.5 g Cap 500 mg Grans for oral liq 125 mg per 5 ml & 250 mg per 5 ml Inj 500 mg & 1 g Inj 750 mg Oral liq 1 mg per ml Tab 10 mg Eye oint 1% Eye drops 0.5% Mouthwash 0.2% Handrub 1% with ethanol 70% Soln 4% Nail-soln 8% Tab 0.5 mg, 2.5 mg & 5 mg Tab 250 mg, 500 mg & 750 mg Tab 20 mg Tab 500 mg Tab 250 mg Cap hydrochloride 150 mg Inj phosphate 150 mg per ml, 4 ml

Brand Name Expiry Date*

Bezalip Bezalip Retard Bicalaccord CareSens N CareSens N POP CareSens II CareSens CareSens N Victrelis Arrow-Brimonidine Zyban Dostinex PSM Miacalcic Arrow-Calcium Calsource DBL Leucovorin Calcium Candestar Poly-Gel Cephalexin ABM Cefalexin Sandoz AFT Multichem Cetirizine - AFT Zetop Chlorsig Chlorafast healthE healthE Orion Apo-Ciclopirox Zapril Cipflox Arrow-Citalopram Apo-Clarithromycin Apo-Clarithromycin Clindamycin ABM Dalacin C 2015 2014 2015

2015 2016 2014 2016 2015 2015 2014 2014 2014 2015 2016 2016 2015 2014 2014 2014 2015 2015 2014 2015 2016 2014 2014 2014 2016

Cefazolin sodium Cefuroxime sodium Cetirizine hydrochloride Chloramphenicol Chlorhexidine gluconate

Ciclopirox olamine Cilazapril Ciprofloxacin Citalopram hydrobromide Clarithromycin Clindamycin

10

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.


Sole Subsidised Supply Products – cumulative to December 2013

Generic Name

Clomiphene citrate Clomipramine hydrochloride Clonidine hydrochloride

Presentation

Tab 50 mg Tab 10 mg & 25 mg Tab 25 mcg Tab 150 mcg Inj 150 mcg per ml, 1 ml Crm 1% Tab 15 mg, 30 mg & 60 mg Tab 500 mcg Crm 10% Tab 50 mg Oral liq 100 mg per ml Tab 50 mg & 100 mg Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs Nasal spray 10 mcg per dose Tab 1 mg & 4 mg Eye oint 0.1%

Brand Name Expiry Date*

Serophene Apo-Clomipramine Clonidine BNM Catapres Clomazol PSM Colgout Itch-Soothe Nausicalm Neoral Siterone Ginet 84 Desmopressin-PH&T Douglas Maxidex Maxitrol Maxitrol 2016 2015 2015

Clotrimazole Codeine phosphate Colchicine Crotamiton Cyclizine hydrochloride Cyclosporin Cyproterone acetate Cyproterone acetate with ethinyloestradiol Desmopressin Dexamethasone

2014 2016 2016 2015 2015 2015 2015 2014 2014 2015 2014 2014

Dexamethasone with neomycin Eye oint 0.1% with neomycin sulphate and polymyxin b sulphate 0.35% and polymyxin B sulphate 6,000 u per g Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per ml Dexamphetamine sulphate Dextrose Dextrose with electrolytes Diclofenac sodium Tab 5 mg Inj 50%, 10 ml Soln with electrolytes; 1,000 ml OP Tab EC 25 mg & 50 mg Tab long-acting 75 mg & 100 mg Inj 25 mg per ml, 3 ml Eye drops 1 mg per ml Suppos 12.5 mg, 25 mg, 50 mg & 100 mg Tab long-acting 60 mg Cap long-acting 120 mg, 180 mg & 240 mg Tab 30 mg & 60 mg Tab long-acting 150 mg Cap 50 mg Cap 120 mg Tab 10 mg

PSM Biomed PedialyteBubblegum Apo-Diclo Diclax SR Voltaren Voltaren Ophtha Voltaren DHC Continus Apo-Diltiazem CD Dilzem Pytazen SR Laxofast 50 Laxofast 120 Prokinex

2015 2014 2016 2015 2014

Dihydrocodeine tartrate Diltiazem hydrochloride

2016 2015

Dipyridamole Docusate sodium Domperidone

2014 2014 2015

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

11


Sole Subsidised Supply Products – cumulative to December 2013

Generic Name

Doxazosin mesylate Doxycycline hydrochloride Emulsifying ointment Enoxaparin sodium Entacapone Ergometrine maleate Etidronate disodium Ethinyloestradiol Ethinyloestradiol with levonorgestrel

Presentation

Tab 2 mg & 4 mg Tab 100 mg Oint BP Inj 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg & 150 mg Tab 200 mg Inj 500 mcg per ml, 1 ml Tab 200 mg Tab 10 mcg Tab 20 mcg with levonorgestrel 100 mcg & 7 inert tab Tab 30 mcg with levonorgestrel 150 mcg & 7 inert tab Tab 25 mg Tab long-acting 5 mg & 10 mg Tab long-acting 2.5 mg Inj 50 mcg per ml, 2 ml & 10 ml Inj 300 mcg per 0.5 ml Inj 480 mcg per 0.5 ml Tab 5 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Cap 250 mg & 500 mg Inj 250 mg, 500 mg & 1 g Cap 50 mg, 150 mg & 200 mg Eye drops 0.1% Crm 5% Metered aqueous nasal spray, 50 mcg per dose Tab 500 mg Tab 40 mg Oint 2% Tab 600 mg Inj 40 mg per ml, 2 ml Tab 80 mg Tab 5 mg Suppos 3.6 g

Brand Name Expiry Date*

Apo-Doxazosin Doxine AFT Clexane Entapone DBL Ergometrine Arrow-Etidronate NZ Medical and Scientific Ava 20 ED Ava 30 ED Aromasin Plendil ER Plendil ER Boucher and Muir Zarzio Zarzio Rex Medical AFT Staphlex Flucloxin Ozole Flucon Efudix Flixonase Hayfever & Allergy Urex Forte Diurin 40 Foban Lipazil Pfizer Apo-Gliclazide Minidiab PSM 2014 2015 2015

31/12/15

2014 2014 2014 2015 2015 2014 2015 2015 2014

Exemestane Felodopine Fentanyl Filgrastim Finasteride Flucloxacillin sodium

2014 2015 2014 2014 2015 2015 2015 2015 2016 2016 2015 2014 2015 2015

Fluconazole Fluorometholone Fluorouracil sodium Fluticasone propionate Furosemide Fusidic acid Gemfibrozil Gentamicin sulphate Gliclazide Glipizide Glycerol

12

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.


Sole Subsidised Supply Products – cumulative to December 2013

Generic Name

Glyceryl trinitrate

Presentation

Aerosol spray 400 mcg per dose TDDS 5 mg & 10 mg Tab 600 mcg Tab 500 mcg, 1.5 mg & 5 mg Oral liq 2 mg per ml Inj 5 mg per ml, 1 ml Inj 100 mg vial Tab 5 mg & 20 mg Crm 1% Powder Rectal foam 10%, CFC-Free (14 applications) Lipocream 0.1% Milky emul 0.1% Oint 0.1% Scalp lotn 0.1% Lotn 1% with wool fat hydrous 3% and mineral oil Inj 1 mg per ml, 1 ml Tab 200 mg Inj 20 mg, 1 ml Tab 10 mg Tab 200 mg Tab long-acting 800 mg Crm 5% Tab 2.5 mg Nebuliser soln, 250 mcg per ml, 1 ml Nebuliser soln, 250 mcg per ml, 2 ml Inj 50 mg per ml, 2 ml Tab 100 mg Tab 20 mg Tab long-acting 40 mg Cap 10 mg & 20 mg Powder for oral soln Cap 100 mg Shampoo 2% Oral liq 10 mg per ml; 240 ml OP Tab 100 mg Cap 15 mg & 30 mg Eye drops 50 mcg per ml Tab 2.5 mg

Brand Name Expiry Date*

Glytrin Nitroderm TTS Lycinate Serenace 2014

Haloperidol

2016

Hydrocortisone

Solu-Cortef Douglas Pharmacy Health ABM Colifoam Locoid Lipocream Locoid Crelo Locoid Locoid DP Lotn HC ABM Hydroxocobalamin Plaquenil Buscopan Gastrosoothe Arrowcare Brufen SR Aldara Dapa-Tabs Univent Ferrum H PSM Ismo 20 Corangin Oratane Konsyl-D Itrazole Sebizole 3TC Zetlam Solox Hysite Letraccord

2016 2015 2014 2015 2015

Hydrocortisone acetate Hydrocortisone butyrate

Hydrocortisone with wool fat and mineral oil Hydroxocobalamin Hydroxychloroquine sulphate Hyoscine N-butylbromide Ibuprofen Imiquimod Indapamide Ipratropium bromide Iron polymaltose Isoniazid Isosorbide mononitrate Isotretinoin Ispaghula (psyllium) husk Itraconazole Ketoconazole Lamivudine Lansoprazole Latanoprost Letrozole

2014 2015 2015 2014 2014 2014 2016 2016 2014 2015 2014 2015 2016 2016 2014 2016 2014 2015 2015 2015

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

13


Sole Subsidised Supply Products – cumulative to December 2013

Generic Name

Levonorgestrel Lidocaine [lignocaine] hydrochloride Lisinopril Lithium carbonate Lodoxamide trometamol Losartan Losartan with hydrochlorothiazide Macrogol Macrogol 400 and propylene glycol Mask for spacer device Mebendazole Mebeverine hydrochloride Medroxyprogesterone acetate Megestrol acetate Methotrexate Methylprednisolone Methylprednisolone acetate Methylprednisolone acetate with lignocaine Mesalazine Metformin hydrochloride Methadone hydrochloride

Presentation

Tab 1.5 mg Subdermal implant (2 x 75 mg rods) Inj 2% ampoule, 5 ml & 20 ml Viscous soln 2% Tab 5 mg, 10 mg & 20 mg Tab 250 mg & 400 mg Cap 250 mg Eye drops 0.1% Tab 12.5 mg, 25 mg, 50 mg & 100 mg Tab 50 mg with hydrochlorothiazide 12.5 mg Powder 13.125 g, sachets Eye drops 0.4% and propylene glycol 0.3%, 0.4 ml Size 2 Tab 100 mg Tab 135 mg Tab 2.5 mg, 5 mg, 10 mg & 100 mg Inj 150 mg per ml, 1 ml syringe Tab 160 mg Inj 25 mg per ml, 2 ml & 20 ml Tab 4 mg & 100 mg Inj 40 mg per ml Inj 40 mg per ml with lignocaine 1 ml Enema 1 g per 100 ml Suppos 500 mg Tab immediate-release 500 mg & 850 mg Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Inj 40 mg per ml, 1 ml; 62.5 mg per ml, 2 ml; 500 mg & 1 g Inj 5 mg per ml, 2 ml Tab 10 mg Tab long-acting 23.75 mg, 47.5 mg, 95 mg & 190 mg

Brand Name Expiry Date*

Postinor-1 Jadelle Lidocaine-Claris Xylocaine Viscous Arrow-Lisinopril Lithicarb FC Douglas Lomide Lostaar Arrow-Losartan & Hydroclorothiazide Lax-Sachets Systane Unit Dose EZ-fit Paediatric Mask De-Worm Colofac Provera Depo-Provera Apo-Megestrol Hospira Medrol Depo-Medrol Depo-Medrol with Lidocaine Pentasa Asacol Apotex Biodone Biodone Forte Biodone Extra Forte Solu-Medrol Pfizer Metamide Metoprolol-AFT CR 2016 31/12/13 2015 2014 2015 2015 2014 2014 2014 2014 2014 2016 2015 2014 2014 2016 2015 2016 2015 2015 2015 2015 2014 2015 2015

Methylprednisolone sodium succinate Metoclopramide hydrochloride Metoprolol succinate

2015 2014 2015

14

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.


Sole Subsidised Supply Products – cumulative to December 2013

Generic Name

Metoprolol tartrate

Presentation

Inj 1 mg per ml, 5 ml Tab 50 mg & 100 mg Tab long-acting 200 mg Tab 50 mg Oral gel 20 mg per g Crm 2% Tab 30 mg & 45 mg Inj 5 mg vial Tab 150 mg & 300 mg Crm 0.1% Oint 0.1% Oral liq 1 mg per ml, 2 mg per ml, 5 mg per ml & 10 mg per ml Tab long-acting 10 mg, 30 mg, 60 mg & 100 mg Inj 5 mg per ml, 1 ml Inj 10 mg per ml, 1 ml Inj 15 mg per ml, 1 ml Inj 30 mg per ml, 1 ml

Brand Name Expiry Date*

Lopresor Lopresor Slow-Lopresor Puri-nethol Decozol Multichem Avanza Arrow Apo-Moclobemide m-Mometasone RA-Morph Arrow-Morphine LA DBL Morphine Sulphate DBL Morphine Sulphate DBL Morphine Sulphate DBL Morphine Sulphate Hospira Naltraccord Naphcon Forte Apo-Nadolol Noflam 250 Noflam 500 AstraZeneca Nevirapine Alphapharm Habitrol Habitrol Habitrol Apo-Nicotinic Acid Noriday 28 Primolut N Arrow-Norfloxacin Norpress 2014 2015 2014 2014 2016 2015

Mercaptopurine Miconazole Miconazole nitrate Mirtazapine Mitomycin C Moclobemide Mometasone furoate Morphine hydrochloride Morphine sulphate

2016 2015 2014 2015 2016 2015 2015 2015 2016 2014

Morphine tartrate Naltrexone hydrochloride Naphazoline hydrochloride Nadolol Naproxen Neostigmine Nevirapine Nicotine

Inj 80 mg per ml, 1.5 ml & 5 ml Tab 50 mg Eye drops 0.1% Tab 40 mg & 80 mg Tab 250 mg Tab 500 mg Inj 2.5 mg per ml, 1 ml Tab 200 mg Gum 2 mg & 4 mg (classic, fruit, mint) Lozenge 1 mg & 2 mg Patch 7 mg, 14 mg & 21 mg Tab 50 mg & 500 mg Tab 350 mcg Tab 5 mg Tab 400 mg Tab 10 mg & 25 mg

2016 2016 2014 2015 2015 2014 2015 2014

Nicotinic acid Norethisterone Norfloxacin Nortriptyline hydrochloride

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

15


Sole Subsidised Supply Products – cumulative to December 2013

Generic Name

Nystatin Octreotide (somatostatin analogue) Oil in water emulsion Omeprazole

Presentation

Oral liq 100,000 u per ml Inj 50 mcg per ml, 1 ml Inj 100 mcg per ml, 1 ml Inj 500 mcg per ml, 1 ml Crm Cap 10 mg, 20 mg & 40 mg Powder Inj 40 mg Tab 10 mg & 15 mg Oral liq 5 mg per ml Tab 5 mg Inj 50 mg per ml, 1 ml Inj 10 mg per ml, 1 ml & 2 ml Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml Inj 3 mg per ml, 10 ml; 6 mg per ml, 10 ml & 9 mg per ml, 10 ml Inj 40 mg Suppos 500 mg Tab 500 mg Oral liq 120 mg per 5 ml Oral liq 250 mg per 5 ml Tab paracetamol 500 mg with codeine phosphate 8 mg Low range & normal range Inj 135 mcg prefilled syringe & inj 180 mcg prefilled syringe Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 112 Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 168 Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 112 Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 168 Tab 0.25 mg & 1 mg Crm 5% Lotn 5%

Brand Name Expiry Date*

Nilstat Octreotide Max Rx 2014 2014

healthE Fatty Cream Omezol Relief Midwest Dr Reddy’s Omeprazole Ox-Pam Apo-Oxybutynin OxyNorm Oxycodone Orion Syntometrine Pamidronate BNM Pantocid IV Paracare Parafast Ethics Paracetamol Paracare Double Strength Paracetamol + Codeine (Relieve) Breath-Alert Pegasys Pegasys RBV Combination Pack Pegasys RBV Combination Pack Pegasys RBV Combination Pack Pegasys RBV Combination Pack Permax Lyderm A-Scabies

2015 2014

Oxazepam Oxybutynin Oxycodone hydrochloride Oxytocin Pamidronate disodium Pantoprazole Paracetamol

2014 2016 2015 2015 2014 2014 2015 2014

Paracetamol with codeine Peak flow meter Pegylated interferon alfa-2a Pegylated interferon alfa-2a

2014 2015 2017 2017

Pergolide Permethrin

2014 2014

16

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.


Sole Subsidised Supply Products – cumulative to December 2013

Generic Name

Pethidine hydrochloride

Presentation

Tab 50 mg & 100 mg Inj 50 mg per ml, 1 ml Inj 50 mg per ml, 2 ml

Brand Name Expiry Date*

PSM DBL Pethidine Hydrochloride DBL Pethidine Hydrochloride PSM Apo-Pindolol Pizaccord Sandomigran Coloxyl Span-K Cholvastin Cilicaine Allersoothe Allersoothe Mestinon PyridoxADE Apo-Pyridoxine Arrow-Quinapril Accuretic 10 Accuretic 20 Peptisoothe Arrow-Ranitidine Mycobutin Norvir Rizamelt ArrowRoxithromycin Asthalin Duolin 2014 2016 2015 2014 2015 2015 2015 2015 2014

Phenobarbitone Pindolol Pioglitazone Pizotifen Poloxamer Potassium chloride Pravastatin Procaine penicillin Promethazine hydrochloride Pyridostigmine bromide Pyridoxine hydrochloride Quinapril Quinapril with hydrochlorothiazide

Tab 15 mg & 30 mg Tab 5 mg, 10 mg & 15 mg Tab 15 mg, 30 mg & 45 mg Tab 500 mcg Oral drops 10% Tab long-acting 600 mg Tab 20 mg & 40 mg Inj 1.5 mega u Oral liq 5 mg per 5 ml Tab 10 mg & 25 mg Tab 60 mg Tab 25 mg Tab 50 mg Tab 5 mg, 10 mg & 20 mg Tab 10 mg with hydrochlorothiazide 12.5 mg Tab 20 mg with hydrochlorothiazide 12.5 mg Oral liq 150 mg per 10 ml Tab 150 mg & 300 mg Cap 150 mg Tab 100 mg Tab orodispersible 10 mg Tab 150 mg & 300 mg Nebuliser soln, 1 mg per ml & 2 mg per ml, 2.5 ml Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml Tab 50 mg & 100 mg Tab 25 mg, 50 mg & 100 mg Tab 10 mg Tab 20 mg Tab 40 mg Tab 80 mg

2015 2016 2015 2015 2014 2015 2014 2014 2015 2014 2014 2015 2015

Ranitidine hydrochloride Rifabutin Ritonavir Rizatriptan Roxithromycin Salbutamol Salbutamol with ipratropium bromide Sertraline Sildenafil Simvastatin

Arrow-Sertraline Silagra Arrow-Simva 10mg Arrow-Simva 20mg Arrow-Simva 40mg Arrow-Simva 80mg

2016 2014 2014

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

17


Sole Subsidised Supply Products – cumulative to December 2013

Generic Name

Sodium chloride Sodium citrate with sodium lauryl sulphoacetate Sodium hyaluronate Spacer device Spironolactone Sulphasalazine Sumatriptan Tamoxifen citrate Tar with triethanolamine lauryl sulphate and fluorescein Temazepam Temozolomide Terazosin Terbinafine Testosterone cypionate Testosterone undecanoate Tetrabenazine Tetracosactrin Timolol maleate Tobramycin

Presentation

Inj 23.4%, 20 ml ampoule Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml Eye drops 1 mg per ml, 10 ml OP 800 ml 230 ml (single patient) Tab 25 mg & 100 mg Tab 500 mg Tab EC 500 mg Tab 50 mg & 100 mg Inj 12 mg per ml, 0.5 ml cartridge Tab 20 mg Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium, 500 ml & 1,000 ml Tab 10 mg Cap 5 mg, 20 mg, 100 mg & 250 mg Tab 1 mg, 2 mg & 5 mg Tab 250 mg Inj long-acting 100 mg per ml, 10 ml Cap 40 mg Tab 25 mg Inj 250 mcg per ml, 1 ml ampoule Inj 1 mg per ml, 1 ml Eye drops 0.25% & 0.5% Eye drops 0.3% Eye oint 0.3% Inj 40 mg per ml, 2 ml Tab 100 mg Cap 50 mg Crm 0.5 mg per g Inj 10 mg per ml, 1 ml Inj 40 mg per ml, 1 ml Crm 0.02% Oint 0.02% 0.1% in Dental Paste USP Eye drops 0.5% & 1% Cap 250 mg Inj 500 mg

Brand Name Expiry Date*

Biomed Micolette Hylo-Fresh Volumatic Space Chamber Plus Spirotone Salazopyrin Salazopyrin EN Arrow-Sumatriptan Genox Pinetarsol 2016 2016 2016 2015 2016 2016 2016 2014 2014

Normison Temaccord Arrow Dr Reddy’s Terbinafine Depo-Testosterone Andriol Testocaps Motetis Synacthen Synacthen Depot Arrow-Timolol Tobrex Tobrex DBL Tobramycin Tasmar Arrow-Tramadol ReTrieve Kenacort-A Kenacort-A40 Aristocort Aristocort Oracort Mydriacyl Ursosan Mylan

2014 2016 2016 2014 2014 2015 2016 2014 2014 2014

Tolcapone Tramadol hydrochloride Tretinoin Triamcinolone acetonide

2014 2014 2016 2014

Tropicamide Ursodeoxycholic acid Vancomycin hydrochloride

2014 2014 2014

18

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.


Sole Subsidised Supply Products – cumulative to December 2013

Generic Name

Verapamil hydrochloride Zidovudine [AZT] Zidovudine [AZT] with lamivudine Zinc and castor oil Zinc sulphate

Presentation

Tab 40 mg & 80 mg Cap 100 mg & oral liq 10 mg per ml Tab 300 mg with lamivudine 150 mg Oint BP Caps 137.4 mg (50 mg elemental)

Brand Name Expiry Date*

Isoptin Retrovir Alphapharm Multichem Zincaps 2014 2016 2014 2014 2014

December changes are in bold type

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

19


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings

Effective 1 December 2013

25 46 MESALAZINE Suppos 1 g ............................................................................ 54.60 30 ✔ Pentasa

EPTACOG ALFA [RECOMBINANT FACTOR VIIA] [Xpharm] Inj 1 mg syringe ................................................................. 1,163.75 1 ✔ NovoSeven RT Inj 2 mg syringe ................................................................ 2,327.50 1 ✔ NovoSeven RT Inj 5 mg syringe ................................................................. 5,818.75 1 ✔ NovoSeven RT Inj 8 mg syringe ................................................................. 9,310.00 1 ✔ NovoSeven RT For patients with haemophilia, whose treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group. MOROCTOCOG ALFA [RECOMBINANT FACTOR VIII] [Xpharm] Inj 250 iu vial ........................................................................ 225.00 1 ✔ Xyntha Inj 500 iu vial......................................................................... 450.00 1 ✔ Xyntha Inj 1,000 iu vial...................................................................... 900.00 1 ✔ Xyntha Inj 2,000 iu vial ................................................................. 1,800.00 1 ✔ Xyntha Inj 3,000 iu vial................................................................... 2,700.00 1 ✔ Xyntha For patients with haemophilia, whose treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group. NONACOG ALFA [RECOMBINANT FACTOR IX] [Xpharm] Inj 250 iu vial......................................................................... 310.00 1 ✔ BeneFIX Inj 500 iu vial......................................................................... 620.00 1 ✔ BeneFIX Inj 1,000 iu vial .................................................................. 1,240.00 1 ✔ BeneFIX Inj 2,000 iu vial................................................................... 2,480.00 1 ✔ BeneFIX For patients with haemophilia, whose treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group. OCTOCOG ALFA [RECOMBINANT FACTOR VIII] [Xpharm] Inj 250 iu vial ........................................................................ 237.50 1 ✔ Advate 250.00 ✔ Kogenate FS Inj 500 iu vial......................................................................... 475.00 1 ✔ Advate 500.00 ✔ Kogenate FS Inj 1,000 iu vial...................................................................... 950.00 1 ✔ Advate 1,000.00 ✔ Kogenate FS Inj 1,500 iu vial................................................................... 1,425.00 1 ✔ Advate Inj 2,000 iu vial................................................................... 1,900.00 1 ✔ Advate 2,000.00 ✔ Kogenate FS Inj 3,000 iu vial................................................................... 2,850.00 1 ✔ Advate 3,000.00 ✔ Kogenate FS For patients with haemophilia, whose treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group. FACTOR EIGHT INHIBITORS BYPASSING AGENT [Xpharm] Inj 500 U ............................................................................ 1,640.00 1 ✔ FEIBA Inj 1,000 U ......................................................................... 3,280.00 1 ✔ FEIBA For patients with haemophilia, whose treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

46

46

46

46

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

20

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings - effective 1 December 2013 (continued)

51 58 COMPOUND ELECTROLYTES Powder for oral soln – Up to 10 sach available on a PSO............ 1.80 SPIRONOLACTONE ❋ Tab 25 mg ............................................................................... 3.65 ❋ Tab 100 mg ............................................................................ 11.80 UREA ❋ Crm 10% ................................................................................... 1.65 OXYTOCIN – Up to 5 inj available on a PSO Inj 5 iu per ml, 1 ml ampoule ..................................................... 4.75 Inj 10 iu per ml, 1 ml ampoule ................................................... 5.98 LAMIVUDINE – Special Authority see SA1364 – Retail pharmacy Tab 150 mg ........................................................................... 52.50 ROPINIROLE HYDROCHLORIDE Tab 0.25 mg ............................................................................ 2.36 Tab 1 mg .................................................................................. 5.32 Tab 2 mg .................................................................................. 7.72 Tab 5 mg ............................................................................... 14.48 PRAMIPEXOLE HYDROCHLORIDE s Tab 0.25 mg ............................................................................. 7.20 s Tab 1 mg ................................................................................ 24.39 GABAPENTIN – Special Authority see SA1071 – Retail pharmacy s Cap 100 mg ............................................................................. 7.16 s Cap 300 mg – For gabapentin oral liquid formulation refer, page 189 ............................................................................ 11.00 s Cap 400 mg ........................................................................... 13.75 10 100 100 100 g OP 5 5 60 ✔ Enerlyte

✔ Spiractin ✔ Spiractin ✔ healthE Urea Cream ✔ Oxytocin BNM ✔ Oxytocin BNM ✔ Lamivudine Alphapharm ✔ Apo-Ropinirole ✔ Apo-Ropinirole ✔ Apo-Ropinirole ✔ Apo-Ropinirole

69 79

105

118 118 126 139

100 100 100 100

100 100 100 100 100

✔ Ramipex S29 ✔ Ramipex S29 ✔ Arrow-Gabapentin ✔ Arrow-Gabapentin ✔ Arrow-Gabapentin

OLANZAPINE – Safety medicine; prescriber may determine dispensing frequency Tab 2.5 mg .............................................................................. 2.00 28 Tab 5 mg .................................................................................. 3.85 28 Tab orodispersible 5 mg ............................................................ 6.36 28 Tab 10 mg ............................................................................... 6.35 28 Tab orodispersible 10 mg ......................................................... 8.76 28

✔ Zypine ✔ Zypine ✔ Zypine ODT ✔ Zypine ✔ Zypine ODT

Effective 1 November 2013

39 LACTULOSE – Only on a prescription ❋ Oral liq 10 g per 15 ml ............................................................... 3.84 500 ml ✔ Laevolac

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

21


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings - effective 1 November 2013 (continued)

69 CETOMACROGOL WITH GLYCEROL Crm 90% with glycerol 10% ...................................................... 6.50 1,000 g OP ✔ Pharmacy Health Sorbolene with Glycerin 90 50 50 ✔ Loxamine ✔ Onrex ✔ Onrex

124 131 137

PAROXETINE HYDROCHLORIDE ❋ Tab 20 mg ................................................................................ 4.32 ONDANSETRON ❋ Tab 4 mg .................................................................................. 5.51 ❋ Tab 8 mg .................................................................................. 6.19

ALPRAZOLAM – Safety medicine; prescriber may determine dispensing frequency Tab 250 mcg ............................................................................ 2.50 50 ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 500 mcg............................................................................. 3.25 50 ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 1 mg .................................................................................. 5.00 50 ‡ Safety cap for extemporaneously compounded oral liquid preparations. METHOTREXATE ❋ Inj 7.5 mg prefilled syringe....................................................... 17.19 ❋ Inj 10 mg prefilled syringe........................................................ 17.25 ❋ Inj 15 mg prefilled syringe........................................................ 17.38 ❋ Inj 20 mg prefilled syringe........................................................ 17.50 ❋ Inj 25 mg prefilled syringe........................................................ 17.63 ❋ Inj 30 mg prefilled syringe........................................................ 17.75 SALBUTAMOL ‡ Oral liq 400 mcg per ml ............................................................ 2.06 1 1 1 1 1 1 150 ml

✔ Xanax ✔ Xanax ✔ Xanax

149 178 207

✔ Methotrexate Sandoz ✔ Methotrexate Sandoz ✔ Methotrexate Sandoz ✔ Methotrexate Sandoz ✔ Methotrexate Sandoz ✔ Methotrexate Sandoz ✔ Ventolin ✔ Ensure

ORAL FEED (POWDER) – Special Authority see SA1228 – Hospital pharmacy [HP3] Powder (vanilla) ..................................................................... 13.00 850 g OP

Effective 1 October 2013

46 52 61 79 CLOPIDOGREL ❋ Tab 75 mg – For clopidogrel oral liquid formulation refer, page 189 .............................................................................. 5.48 ENALAPRIL MALEATE ❋ Tab 5 mg ................................................................................. 1.19 ❋ Tab 10 mg ............................................................................... 1.47 ❋ Tab 20 mg – For enalapril maleate oral liquid formulation refer, page 189 ............................................................................... 1.91 HYDRALAZINE HYDROCHLORIDE ❋ Inj 20 mg ampoule .................................................................. 25.90 84 100 100 100 ✔ Arrow - Clopid ✔ Ethics Enalapril ✔ Ethics Enalapril ✔ Ethics Enalapril

5

✔ Apresoline s29 S29 ✔ Tamsulosin-Rex

TAMSULOSIN HYDROCHLORIDE – Special Authority see SA1032 – Retail pharmacy ❋ Cap 400 mcg .......................................................................... 13.51 100

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

22

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings - effective 1 October 2013 (continued)

119 RILUZOLE– Special Authority see SA1403 – Retail pharmacy – Wastage rule applies Tab 50 mg ............................................................................ 400.00 56 ✔ Rilutek

➽ SA1403 Special Authority for Subsidy Initial application only from a neurologist or respiratory specialist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has amyotrophic lateral sclerosis with disease duration of 5 years or less; and 2 The patient has at least 60 percent of predicted forced vital capacity within 2 months prior to the initial application; and 3 The patient has not undergone a tracheostomy; and 4 The patient has not experienced respiratory failure; and 5 Any of the following: 5.1 The patient is ambulatory; or 5.2 The patient is able to use upper limbs; or 5.3 The patient is able to swallow. Renewal from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria: All of the following: 1 The patient has not undergone a tracheostomy, and 2 The patient has not experienced respiratory failure; and 3 Any of the following: 3.1 The patient is ambulatory; or 3.2 The patient is able to use upper limbs; or 3.3 The patient is able to swallow. 123 MAPROTILINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency Tab 75 mg – wastage rule applies ........................................... 14.01 20 ✔ Ludiomil s29 S29 CYCLOPHOSPHAMIDE Tab 50 mg – PCT – Retail pharmacy-Specialist – wastage rule applies ....................................................... 158.00 TAMOXIFEN CITRATE ❋ Tab 10 mg ............................................................................... 2.63 ❋ Tab 20 mg ............................................................................... 2.63 Note – these are new packsizes with new Pharmacodes. LORATADINE ❋ Tab 10 mg ................................................................................ 1.30

147

100 60 30

✔ Procytox S29 ✔ Genox ✔ Genox

160 176

100

✔ Lorafix

Effective 1 September 2013

25 82 MESALAZINE Modified release granules, 1 g ............................................... 141.72 TETRACOSACTRIN ❋ Inj 250 mcg per ml, 1 ml ampoule ........................................... 17.71 120 g OP 1 ✔ Pentasa ✔ Synacthen

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

23


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings - effective 1 September 2013 (continued)

87 DESMOPRESSIN Tab 100 mcg – Special Authority see SA1401 – Retail pharmacy................................................................ 36.40 Tab 200 mcg – Special Authority see SA1401 – Retail pharmacy................................................................ 93.60

30 30

✔ Minirin ✔ Minirin

➽ SA1401 Special Authority for Subsidy Initial application (Nocturnal enuresis) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: 1. The patient has primary nocturnal enuresis; and 2. The nasal forms of desmopressin are contraindicated; and 3. An enuresis alarm is contraindicated. Initial application (Diabetes insipidus) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: 1. The patient has cranial diabetes insipidus; and 2. The nasal forms of desmopressin are contraindicated Renewal from any relevant practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment. 98 BOCEPREVIR – Special Authority see SA1365 – Retail pharmacy – Wastage rule applies Cap 200 mg ....................................................................... 5,015.00 336 ✔ Victrelis ➽ SA1365 Special Authority for Subsidy Initial application — (chronic hepatitis C – genotype 1, first-line) from gastroenterologist, infectious disease physician or general physician Approvals valid for 18 months for applications meeting the following criteria: All of the following: 1 Patient has chronic hepatitis C, genotype 1; and 2 Patient has not received prior pegylated interferon treatment; and 3 Patient has IL-28B genotype CT or TT; and 4 Patient is to be treated in combination with pegylated interferon and ribavirin; and 5 Patient is hepatitis C protease inhibitor treatment-naive; and 6 Maximum of 44 weeks therapy. Initial application — (chronic hepatitis C – genotype 1, second-line) from gastroenterologist, infectious disease physician or general physician. Approvals valid for 18 months for applications meeting the following criteria: All of the following: 1 Patient has chronic hepatitis C, genotype 1; and 2 Patient has received pegylated interferon treatment; and 3 Any of the following: 3.1. Patient was a responder relapser; or 3.2. Patient was a partial responder; or 3.3. Patient received pegylated interferon prior to 2004; and 4 Patient is to be treated in combination with pegylated interferon and ribavirin; and 5 Maximum of 44 weeks therapy. Note: Due to risk of severe sepsis boceprevir should not be initiated if either Platelet count <100 x109 /l or Albumin <35 g/l. Note: the wastage rule applies to boceprevir to allow dispensing to occur more frequently than monthly. 113 RISEDRONATE SODIUM Tab 35 mg ............................................................................... 4.00 4 ✔ Risedronate Sandoz

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

24

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings - effective 1 September 2013 (continued)

123 IMIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency – Wastage rule applies Tab 10 mg ................................................................................ 6.58 60 ✔ Tofranil S29 S29 THIOTEPA – PCT only – Specialist Inj 15 mg ............................................................................. CBS PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN ❋ Eye oint with soft white paraffin ................................................. 3.63 PHARMACY SERVICES – May only be claimed once per patient Brand switch fee ....................................................................... 4.33 The Pharmacode for BSF Acetec is 2445441

148

1 3.5 g OP 1 fee

✔ Tepadina S29 ✔ Refresh Night Time ✔ BSF Acetec

186 187

202

PAEDIATRIC ORAL FEED 1KCAL/ML – Special Authority see SA1379 – Hospital pharmacy [HP3] Liquid (chocolate) .................................................................... 1.07 200 ml OP ✔ Pediasure Liquid (strawberry) .................................................................... 1.07 200 ml OP ✔ Pediasure Liquid (vanilla) .......................................................................... 1.07 200 ml OP ✔ Pediasure Note – the packaging has changed to Recloseable Plastic Bottle (RPB) with new Pharmacodes. PAEDIATRIC ORAL FEED 1KCAL/ML – Special Authority see SA1379 – Hospital pharmacy [HP3] Liquid (vanilla) .......................................................................... 1.34 250 ml OP ✔ Pediasure

202

Effective 12 August 2013

52 ENALAPRIL MALEATE ❋ Tab 5 mg ................................................................................. 0.36 5.94 ❋ Tab 10 mg ............................................................................... 0.44 7.33 ❋ Tab 20 mg – For enalapril maleate oral liquid formulation refer, page 189 ............................................................................... 0.57 30 500 30 500 30 ✔ Acetec ✔ Acetec ✔ Acetec ✔ Acetec ✔ Acetec

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

25


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions, Chemical Names and Presentations

Effective 1 December 2013

51 COMPOUND ELECTROLYTES (amend the presentation description) Powder for oral soln for oral use 4.4 g – Up to 10 sach available on a PSO ............................................................................... 1.12 1.80 ENALAPRIL MALEATE – Brand switch fee payable (Pharmacode 2445441) ❋ Tab 5 mg .................................................................................. 0.36 5.94 ❋ Tab 10 mg ................................................................................ 0.44 7.33 ❋ Tab 20 mg – For enalapril maleate oral liquid formulation refer, page 189 ............................................................................... 0.57 CETOMACROGOL WITH GLYCEROL (amendment to units of measure) Crm 90% with glycerol 10% ....................................................... 4.50 5 10 30 500 30 500 30 ✔ Electral ✔ Enerlyte ✔ Acetec ✔ Acetec ✔ Acetec ✔ Acetec ✔ Acetec

52 68

500 g ml OP ✔ Pharmacy Health Sorbolene with Glycerin 6.50 1,000 g ml OP ✔ Pharmacy Health Sorbolene with Glycerin ✔ Syntocinon ✔ Oxytocin BNM ✔ Syntocinon ✔ Oxytocin BNM ✔ Neo-Mercazole ✔ E-Mycin ✔ E-Mycin

79

OXYTOCIN – Up to 5 inj available on a PSO (amend the presentation description) Inj 5 iu per ml, 1 ml ampoule ..................................................... 5.94 5 4.75 Inj 10 iu per ml, 1 ml ampoule ................................................... 7.48 5 5.98 CARBIMAZOLE (removal of STAT) Tab 5 mg ............................................................................... 10.80 ERYTHROMYCIN ETHYL SUCCINATE Tab 400 mg ............................................................................ 16.95 a) Up to 20 30 tab available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see rule 5.2.6 Grans for oral liq 200 mg per 5 ml ............................................ 4.35 a) Up to 300 200 ml available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see rule 5.2.6 AMOXYCILLIN Cap 250 mg ............................................................................ 16.18 a) Up to 30 cap available on a PSO b) Up to 10 x the maximum PSO quantity for RFPP – see rule 5.2.6 Cap 500 mg ............................................................................ 26.50 a) Up to 30 cap available on a PSO b) Up to 10 x the maximum PSO quantity for RFPP – see rule 5.2.6 Grans for oral liq 250 mg per 5 ml ............................................. 1.10 a) Up to 300 200 ml available on a PSO b) Up to 10 x the maximum PSO quantity for RFPP – see rule 5.2.6 100 100 100 ml

85 89

90

500 500 100 ml

✔ Alphamox ✔ Alphamox ✔ Ospamox

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

26

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 December 2013 (continued)

91 PHENOXYMETHYLPENICILLIN (PENICILLIN V) Cap potassium salt 500 mg .................................................... 11.70 a) Up to 20 cap available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see rule 5.2.6 Grans for oral liq 250 mg per 5 ml ............................................. 1.78 a) Up to 300 200 ml available on a PSO b) Up to 2 x the maximum PSO quantity for RFPP – see rule 5.2.6 50 100 ml ✔ Cilicaine VK ✔ AFT

118

BENZBROMARONE – Special Authority see SA1319 – Retail pharmacy (addition of note) Tab 100 mg ............................................................................ 45.00 100 ✔ Benzbromaron AL 100 S29 ➽ SA1319 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Any of the following: 1.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and appropriate doses of probenecid; or 1.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite appropriate doses of probenecid; or 1.3 Both: 1.3.1 The patient has renal impairment and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); and 1.3.2 The patient has a rate of creatinine clearance greater than or equal to 20 ml/min; or 1.4 All of the following: 1.4.1 The patient is taking azathioprine and requires urate-lowering therapy; and 1.4.2 Allopurinol is contraindicated; and 1.4.3 Appropriate doses of probenecid are ineffective or probenecid cannot be used due to reduced renal function; and 2 The patient is receiving monthly liver function tests. Renewal from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefitting from the treatment; and 2 There is no evidence of liver toxicity and patient is continuing to receive regular (at least every three months) liver function tests. Notes: Benzbromarone has been associated with potentially fatal hepatotoxicity. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose. The New Zealand Rheumatology Association has developed information for prescribers which can be accessed from its website at http://www.rheumatology.org.nz/benzbromarone_prescriber_information.cfm

118

ROPINIROLE HYDROCHLORIDE (removal of certified exemption) Tab 0.25 mg ............................................................................. 2.36 6.20 Tab 1 mg .................................................................................. 5.32 15.95 Tab 2 mg .................................................................................. 7.72 24.95 Tab 5 mg ................................................................................ 14.48 38.00

84 84 84 84

✔ Apo-Ropinirole ✔ Ropin ✔ Apo-Ropinirole ✔ Ropin ✔ Apo-Ropinirole ✔ Ropin ✔ Apo-Ropinirole ✔ Ropin

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

27


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 December 2013 (continued)

144 NALTREXONE HYDROCHLORIDE – Special Authority see SA14081397 – Retail pharmacy Tab 50 mg .............................................................................. 76.00 30 ✔ Naltraccord ➽ SA14081397 Special Authority for Subsidy Initial application from any relevant medical practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence; and 2 Applicant works in or with a community Alcohol and Drug Service contracted to one of the District Health Boards or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard. Renewal from any relevant medical practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Compliance with the medication (prescriber determined); and 2 Any of the following: 2.1 Patient is still unstable and requires further treatment; or 2.2 Patient achieved significant improvement but requires further treatment; or 2.3 Patient is well controlled but requires maintenance therapy. 155 180 IMATINIB MESILATE MESYLATE – Special Authority see SA0643 (amendment to chemical name) Tab 100 mg ...................................................................... 2,400.00 60 ✔ Glivec MONTELUKAST – Special Authority see SA14091227 – Retail pharmacy Prescribing Guideline: Clinical evidence indicates that the effectiveness of montelukast is strongest when montelukast is used in short treatment courses. Tab 4 mg ............................................................................... 18.48 28 ✔ Singulair Tab 5 mg ................................................................................ 18.48 28 ✔ Singulair Tab 10 mg ............................................................................. 18.48 28 ✔ Singulair ➽ SA14091227 Special Authority for Subsidy Initial application (Pre-school wheeze) from any relevant practitioner. Approvals valid for one year for applications meeting the following criteria: All of the following Both: 1 To be used for the treatment of intermittent severe wheezing (possibly viral) in children under 5 years; and 2 The patient has trialled inhaled corticosteroids at a dose of up to 400 µg per day beclomethasone or budesonide, or 200 µg per day fluticasone for at least one month; and 3 The patient continues to have has had at least three episodes in the previous 12 months of acute wheeze severe enough to seek medical attention. severe exacerbations at least one of which required hospitalisation defined as in-patient stay or prolonged Emergency Department treatment) in the past 12 months. Renewal (pre-school wheeze) - only from a relevant practitioner. Approvals valid for two years where the treatment remains appropriate and the patient is benefitting from treatment. Initial application (exercise-induced asthma) from any relevant practitioner. Approvals valid without further renewal, unless notified, for applications meeting the following criteria: Both: 1 Patient is being treated has been trialled with maximal asthma therapy, including inhaled corticosteroids and long-acting beta-adrenoceptor agonists; and 2 Patient continues to receive optimal inhaled corticosteroid therapy; and 3 Patient continues to experience frequent episodes of exercise-induced bronchoconstriction. Initial application (aspirin desensitisation) only from a clinical immunologist or allergist. Approvals valid for one year, for applications meeting the following criteria: All of the following: continued... Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

28


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 December 2013 (continued)

continued... 1 Patient is undergoing aspirin desensitisation therapy under the supervision of a clinical immunologist or allergist; and 2 Patient has moderate to severe aspirin-exacerbated respiratory disease or Samter's triad; and 3 Nasal polyposis, confirmed radiologically or surgically; and 4 Documented aspirin or NSAID allergy confirmed by aspirin challenge or a clinical history of severe reaction to aspirin or NSAID where challenge would be considered dangerous.

Effective 1 November 2013

61 101 HYDRALAZINE HYDROCHLORIDE (remove the S29 symbol) ❋ Inj 20 mg ampoule .................................................................. 25.90 VALGANCICLOVIR – Special Authority see SA14041274 – Retail pharmacy Tab 450 mg ...................................................................... 3,000.00 5 60 ✔ Apresoline s29 S29 ✔ Valcyte

➽ SA14041274 Special Authority for Subsidy Initial application - (transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 3 months where the patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis Renewal application - (transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis; and 2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin Initial application - (cytomegalovirus prophylaxis following anti-thymocyte globulin) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Patient has undergone a solid organ transplant and received valganciclovir under Special Authority more than 2 years ago (27 months); and 2 Patient has received anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis Renewal - (cytomegalovirus prophylaxis following anti-thymocyte globulin) only from a relevant specialist. Approvals valid for 3 months where the patient has received a further course of anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis. Initial application - (Lung transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1. Patient has undergone a lung transplant; and 2. Either: 2.1. The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or 2.2. The recipient is cytomegalovirus positive. Initial application - (Cytomegalovirus in immunocompromised patients) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1. Patient is immunocompromised; and 2. Any of the following 2.1. Patient has cytomegalovirus syndrome or tissue invasive disease, or 2.2. Patient has rapidly rising plasma CMV DNA in absence of disease; or 2.3. Patient has cytomegalovirus retinitis continued...

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

29


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 November 2013 (continued)

continued... Note: for the purpose of this Special Authority "immunocompromised" includes transplant recipients, patients with immunosuppressive diseases (e.g. HIV) or those receiving immunosuppressive treatment for other conditions Renewal application - (Cytomegalovirus in immunocompromised patients) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1. Patient is immunocompromised; and 2. Any of the following 2.1. Patient has cytomegalovirus syndrome or tissue invasive disease, or 2.2. Patient has rapidly rising plasma CMV DNA in absence of disease; or 2.3. Patient has cytomegalovirus retinitis Note: for the purpose of this Special Authority "immunocompromised" includes transplant recipients, patients with immunosuppressive diseases (e.g. HIV) or those receiving immunosuppressive treatment for other conditions 123 MAPROTILINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency (remove the S29 symbol) Tab 75 mg – wastage rule applies ........................................... 14.01 20 ✔ Ludiomil s29 S29 IMIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency – wastage rule applies (remove the S29 symbol) Tab 10 mg ............................................................................... 6.58 60 ✔ Tofranil s29 S29 SALBUTAMOL (amendment to presentation description) ‡ Oral liq 2 mg per 5 ml 400 mcg per ml ....................................... 1.99 2.06 150 ml ✔ Salapin ✔ Ventolin

123

178

Effective 1 October 2013

52 ENALAPRIL MALEATE (addition of STAT dispensing) ❋ Tab 5 mg .................................................................................. 0.36 1.07 1.19 5.94 ❋ Tab 10 mg ................................................................................ 0.44 1.32 1.47 7.33 ❋ Tab 20 mg – For enalapril maleate oral liquid formulation refer, page 189 ............................................................................... 0.57 1.72 1.91 Note: the removal of the stat symbol will be temporary due to a stock recall 30 90 100 500 30 90 100 500 30 90 100 ✔ Acetec ✔ m-Enalapril ✔ Ethics Enalapril ✔ Acetec ✔ Acetec ✔ m-Enalapril ✔ Ethics Enalapril ✔ Acetec ✔ Acetec ✔ m-Enalapril ✔ Ethics Enalapril

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

30

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 October 2013 (continued)

52 PERINDOPRIL (removal of subsidy by endorsement) From 1 August 2013 to 30 September 2013 the Coversyl brand of perindopril will be funded by Endorsement to the level of the ex-manufacturer price listed in the Schedule for patients who were previously accessing the higher subsidy by endorsement for perindopril prior to 1 May 2013. ❋ Tab 2 mg – Higher subsidy of up to $18.50 per 30 tab with Endorsement ......................................................................... 3.75 30 ✔ Apo-Perindopril (18.50) Coversyl ❋ Tab 4 mg – Higher subsidy of up to $25.00 per 30 tab with Endorsement ......................................................................... 4.80 30 ✔ Apo-Perindopril (25.00) Coversyl ZOLEDRONIC ACID – Special Authority see SA1187 – Retail pharmacy (addition of OP) Soln for infusion 5 mg in 100 ml ............................................ 600.00 100 ml OP ✔ Aclasta OXYCODONE HYDROCHLORIDE (amendment to presentation description) a) Only on a controlled drug form b) See prescribing guideline c) No patient co-payment payable d) Safety medicine; prescriber may determine dispensing frequency Cap immediate-release 5 mg .................................................. 2.83 Cap immediate-release 10 mg ................................................ 5.58 Cap immediate-release 20 mg ................................................ 9.77

115 122

20 20 20

✔ OxyNorm ✔ OxyNorm ✔ OxyNorm

130

HYOSCINE HYDROBROMIDE HYOSCINE (SCOPOLAMINE) – Special Authority see SA1387 – Retail pharmacy (change to chemical name) Patch 1.5 mg .......................................................................... 11.95 2 ✔ Scopoderm TTS

Effective 1 September 2013

52 ENALAPRIL MALEATE – Brand switch fee payable (Pharmacode 2445441) - see page 187 for details Tab 5 mg .................................................................................. 0.36 30 ✔ Acetec 1.07 90 ✔ m-Enalapril 5.94 500 ✔ Acetec Tab 10 mg ................................................................................ 0.44 30 ✔ Acetec 1.32 90 ✔ m-Enalapril 7.33 500 ✔ Acetec Tab 20 mg – For enalapril maleate oral liquid formulation refer, page 189 ............................................................................... 0.57 30 ✔ Acetec 1.72 90 ✔ m-Enalapril Note: the removal of the stat symbol will be temporary due to a stock recall TETRACOSACTRIN (amendment to presentation) ❋ Inj 250 mcg per ml, 1 ml ampoule .......................................... 17.71 177.18 1 10 ✔ Synacthen ✔ Synacthen

82 106

Guidelines for the use of interferon in the treatment of hepatitis C: Physicians considering treatment of patients with hepatitis C should discuss cases with a gastroenterologist or an infectious disease physician. All subjects undergoing treatment require careful monitoring for side effects. Patients should be otherwise fit. Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level. Criteria for Treatment 1) Diagnosis continued... ❋ Three months or six months, as applicable, dispensed all-at-once

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

31


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2013 (continued)

continued... • Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by a supplementary RIBA test; or • PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or • Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR for HCV RNA but with a liver biopsy consistent with 2(b) following. Exclusion Criteria 1) Autoimmune liver disease. (Interferon may exacerbate autoimmune liver disease as well as other autoimmune diseases such as thyroid disease). 2) Pregnancy. 3) Neutropenia (<2.0 × 109) and/or thrombocytopenia. 4) Continuing alcohol abuse and/or continuing intravenous drug users. Dosage The current recommended dosage is 3 million units of interferon alfa-2a alpha-2a or interferon alpha-2b alfa-2b administered subcutaneously 3 times a week for 52 weeks (twelve months) Exit Criteria The patient’s response to interferon treatment should be reviewed at either three or four months. Interferon treatment should be discontinued in patients who do not show a substantial reduction (50%) in their mean pretreatment ALlevel at this stage. 107 INTERFERON ALFA-2A ALPHA-2A – PCT – Retail pharmacy-Specialist (amendment to chemical name) a) See prescribing guideline b) Prescriptions must be written by, or on the recommendation of, an internal medicine physician or ophthalmologist Inj 3 m iu prefilled syringe ....................................................... 31.32 1 ✔ Roferon-A Inj 6 m iu prefilled syringe ....................................................... 62.64 1 ✔ Roferon-A Inj 9 m iu prefilled syringe ....................................................... 93.96 1 ✔ Roferon-A INTERFERON ALFA-2B ALPHA-2B – PCT – Retail pharmacy-Specialist (amendment to chemical name) a) See prescribing guideline b) Prescriptions must be written by, or on the recommendation of, an internal medicine physician or ophthalmologist Inj 18 m iu, 1.2 ml multidose pen .......................................... 187.92 1 ✔ Intron-A Inj 30 m iu, 1.2 ml multidose pen .......................................... 313.20 1 ✔ Intron-A Inj 60 m iu, 1.2 ml multidose pen .......................................... 626.40 1 ✔ Intron-A PEGYLATED INTERFERON ALFA-2A ALPHA-2A – Special Authority see SA14001365 – Retail pharmacy See prescribing guideline Inj 135 mcg prefilled syringe ............................................... 1,448.00 4 Inj 180 mcg prefilled syringe .................................................. 900.00 4 Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 112 ......................................................... 1,159.84 1 OP Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 168 ........................................................ 1,290.00 1 OP

107

107

✔ Pegasys ✔ Pegasys ✔ Pegasys RBV Combination Pack ✔ Pegasys RBV Combination Pack

➽ SA14001365 Special Authority for Subsidy Initial application — (chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant) from any specialist. Approvals valid for 18 months for applications meeting the following criteria: continued... Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

32


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2013 (continued)

continued... Both: 1. Any of the following: 1.1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or 1.2 Patient has chronic hepatitis C and is co-infected with HIV; or 1.3 Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant; and 2. Maximum of 48 weeks therapy. Notes: Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure. Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml. Renewal application — (Chronic hepatitis C – genotype 1 infection) from gastroenterologist, infectious disease physician or general physician. Approvals valid for 18 months for patients meeting the following criteria: All of the following: 1 Patient has chronic hepatitis C, genotype 1; and 2 Patient has had previous treatment with pegylated interferon and ribavirin; and 3 Either: 3.1 Patient has responder relapsed; or 3.2 Patient was a partial responder; and 4 Patient is to be treated in combination with boceprevir; and 5 Maximum of 48 weeks therapy. Initial application (Chronic Hepatitis C – genotype 1 infection treatment more than 4 years prior) from a gastroenterologist, infectious disease physician or general physician. Approvals valid for 18 months for patients meeting the following criteria: All of the following 1. Patient has chronic hepatitis C, genotype 1; and 2. Patient has had previous treatment with pegylated interferon and ribavirin; and 3. Any of the following: 3.1. Patient has responder relapsed; or 3.2. Patient was a partial responder; or 3.3. Patient received interferon treatment prior to 2004; and 4. Patient is to be treated in combination with boceprevir; and 5. Maximum of 48 weeks therapy. Initial application — (chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1. Patient has chronic hepatitis C, genotype 2 or 3 infection; and 2. Maximum of 6 months therapy. Initial application — (Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria: All of the following: 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and 2 Patient is Hepatitis B treatment-naive; and 3 ALT > 2 times Upper Limit of Normal; and 4 HBV DNA < 10 log10 IU/ml; and 5 Either: 5.1 HBeAg positive; or 5.2 serum HBV DNA ≥ 2,000 units/ml and significant fibrosis (≥ Metavir Stage F2 or moderate fibrosis); and 6 Compensated liver disease; and 7 No continuing alcohol abuse or intravenous drug use; and continued...

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

33


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2013 (continued)

continued... 8 Not co-infected with HCV, HIV or HDV; and 9 Neither ALT nor AST > 10 times upper limit of normal; and 10 No history of hypersensitivity or contraindications to pegylated interferon; and 11 Maximum of 48 weeks therapy. Notes: Approved dose is 180 mcg once weekly. The recommended dose of Pegylated Interferon-alpha 2a Interferon alfa-2a is 180 mcg once weekly. In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferonalpha 2a Interferon alfa-2a dose should be reduced to 135 mcg once weekly. In patients with neutropaenia and thrombocytopaenia, dose should be reduced in accordance with the datasheet guidelines. Pegylated Interferon-alpha 2a Interferon alfa-2a is not approved for use in children. 125 VENLAFAXINE – Special Authority see SA1061 – Retail pharmacy Tab 37.5 mg ............................................................................ 5.06 Tab 75 mg ................................................................................ 6.44 Tab 150 mg .............................................................................. 8.86 Tab 225 mg ............................................................................ 14.34 Cap 37.5 mg – Special Authority see SA1061 – Retail pharmacy ................................................................ 8.71 Cap 75 mg – Special Authority see SA1061 – Retail pharmacy .............................................................. 17.42 Cap 150 mg – Special Authority see SA1061 – Retail pharmacy .............................................................. 21.35 RISPERIDONE – Special Authority see SA0927 – Retail pharmacy Safety medicine; prescriber may determine dispensing frequency Tab orodispersible Orally-disintegrating tablets 0.5 mg ........... 21.42 Tab orodispersible Orally-disintegrating tablets 1 mg ............. 42.84 Tab orodispersible Orally-disintegrating tablets 2 mg ............. 85.71 CYTARABINE Inj 100 mg 20 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist ..................................... 55.00 80.00 Inj 1 g 100 mg per ml, 10 ml vial – PCT – Retail pharmacy-Specialist .................................................. 8.83 42.65 Inj 2 g 100 mg per ml, 20 ml vial – PCT – Retail pharmacy-Specialist ................................................ 17.65 34.47 28 28 28 28 28 28 28 ✔ Arrow-Venlafaxine XR ✔ Arrow-Venlafaxine XR ✔ Arrow-Venlafaxine XR ✔ Arrow-Venlafaxine XR ✔ Efexor XR ✔ Efexor XR ✔ Efexor XR

136

28 28 28

✔ Risperdal Quicklet ✔ Risperdal Quicklet ✔ Risperdal Quicklet

148

5 1 1

✔ Pfizer ✔ Mayne ✔ Pfizer ✔ Mayne ✔ Pfizer ✔ Mayne

204

PAEDIATRIC ENTERAL FEED WITH FIBRE 0.76 0.75 KCAL/ML – Special Authority see SA1196 – Hospital pharmacy [HP3] Liquid ........................................................................................ 4.00 500 ml OP ✔ Nutrini Low Energy Multi Fibre

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

34

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price

Effective 1 December 2013

46 CLOPIDOGREL ( subsidy) ❋ Tab 75 mg – For clopidogrel oral liquid formulation refer, page 189................................................................................... 5.87 (16.25)

90 Apo-Clopidogrel

79 122

TAMSULOSIN HYDROCHLORIDE – Special Authority see SA1032 – Retail pharmacy ( subsidy) ❋ Cap 400 mcg ........................................................................... 4.05 30 (5.98) Tamsulosin-Rex MORPHINE SULPHATE ( subsidy) a) Only on a controlled drug form b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing frequency Cap long-acting 10 mg .............................................................. 1.70 Cap long-acting 30 mg .............................................................. 2.50 Cap long-acting 60 mg .............................................................. 5.40 Cap long-acting 100 mg ............................................................ 6.38 LORATADINE ( subsidy) ❋ Tab 10 mg ................................................................................ 1.30 (2.09)

10 10 10 10 100

✔ m-Eslon ✔ m-Eslon ✔ m-Eslon ✔ m-Eslon

176

Loraclear Hayfever Relief

Effective 1 November 2013

137 ALPRAZOLAM – Safety medicine; prescriber may determine dispensing frequency ( subsidy) Tab 250 mcg............................................................................. 2.50 50 ✔ Arrow-Alprazolam ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 1 mg ................................................................................. 5.00 50 ✔ Arrow-Alprazolam ‡ Safety cap for extemporaneously compounded oral liquid preparations. MYCOPHENOLATE MOFETIL - Special Authority see SA1041 – Retail pharmacy ( subsidy) Dispensing pharmacy should check which brand to dispense with the prescriber if prescribed generically. Tab 500 mg ............................................................................ 25.00 50 ✔ Myaccord (60.00) Ceptolate Cap 250 mg ............................................................................ 12.50 (30.00) 25.00 50 100 Ceptolate ✔ Myaccord

161

Effective 1 October 2013

78 88 CLOTRIMAZOLE ❋ Vaginal crm 1% with applicators ( subsidy) .............................. 1.45 ❋ Vaginal crm 2% with applicators ( subsidy).............................. 2.20 CEFACLOR MONOHYDRATE ( subsidy) Cap 250 mg ............................................................................ 26.00 35 g OP 20 g OP 100 ✔ Clomazol ✔ Clomazol ✔ Ranbaxy-Cefaclor

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

35


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer's Price - effective 1 October 2013 (continued)

122 OXYCODONE HYDROCHLORIDE ( subsidy) a) Only on a controlled drug form b) See prescribing guideline c) No patient co-payment payable d) Safety medicine; prescriber may determine dispensing frequency Tab controlled-release 10 mg .................................................... 6.75 (11.14) Tab controlled-release 20 mg ................................................. 11.50 (18.93) Tab controlled-release 40 mg ................................................. 18.50 (33.29) Tab controlled-release 80 mg .................................................. 34.00 (58.03)

20 OxyContin 20 OxyContin 20 OxyContin 20 OxyContin

Effective 1 September 2013

42 42 VITAMIN B COMPLEX ( subsidy) ❋ Tab, strong, BPC ....................................................................... 4.30 ASCORBIC ACID ( subsidy) a) No more than 100 mg per dose b) Only on a prescription ❋ Tab 100 mg .............................................................................. 7.00 VITAMINS ( subsidy) ❋ Tab (BPC cap strength) ............................................................. 7.60 POTASSIUM IODATE ( subsidy) ❋ Tab 256 mcg (150 mcg elemental iodine) ................................. 6.53 DEXTROSE WITH ELECTROLYTES ( subsidy) Soln with electrolytes ................................................................ 6.55 PINDOLOL ( subsidy) ❋ Tab 5 mg ................................................................................. 9.72 ❋ Tab 10 mg ............................................................................ 15.62 ❋ Tab 15 mg ............................................................................. 23.46 GEMFIBROZIL ( subsidy) ❋ Tab 600 mg ............................................................................ 17.60 500 ✔ B-PlexADE ✔ Bplex

42 43 51

500

✔ Vitala-C ✔ Cvite ✔ MultiADE ✔ Mvite ✔ NeuroKare

1,000

90

1,000 ml OP ✔ Pedialyte – Bubblegum 100 100 100 60 ✔ Apo-Pindolol ✔ Apo-Pindolol ✔ Apo-Pindolol ✔ Lipazil

56 59 105

LAMIVUDINE – Special Authority see SA1364 – Retail pharmacy ( subsidy) Oral liq 10 mg per ml ............................................................. 102.50 240 ml OP ✔ 3TC

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

36

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer's Price - effective 1 September 2013 (continued)

107 PEGYLATED INTERFERON ALFA-2A – Special Authority see SA1400 – Retail pharmacy ( subsidy) See prescribing guideline Inj 180 mcg prefilled syringe .................................................. 900.00 4 ✔ Pegasys Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 112 ............................................................................ 1,159.84 1 OP ✔ Pegasys RBV Combination Pack Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 168 ........................................................................... 1,290.00 1 OP ✔ Pegasys RBV Combination Pack LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE ( subsidy) Inj 1%, 5 ml ampoule – Up to 25 inj available on a PSO ............ 17.50 (35.00) Inj 1%, 20 ml ampoule – Up to 5 inj available on a PSO ............ 12.00 (20.00) VENLAFAXINE ( subsidy) Tab 37.5 mg ............................................................................ 5.06 Tab 75 mg ................................................................................ 6.44 Tab 150 mg ............................................................................. 8.86 Tab 225 mg ............................................................................ 14.34 CYTARABINE ( subsidy) Inj 20 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist ................................................ 55.00 Inj 100 mg per ml, 10 ml vial – PCT – Retail pharmacy-Specialist .................................................. 8.83 Inj 100 mg per ml, 20 ml vial – PCT – Retail pharmacy-Specialist ................................................ 17.65 Inj 1 mg for ECP – PCT only – Specialist ................................... 0.11 Inj 100 mg intrathecal syringe for ECP – PCT only – Specialist.......................................................................... 11.00 50 Xylocaine 5 Xylocaine 28 28 28 28 ✔ Arrow-Venlafaxine XR ✔ Arrow-Venlafaxine XR ✔ Arrow-Venlafaxine XR ✔ Arrow-Venlafaxine XR

119

125

148

5 1 1 10 mg

✔ Pfizer ✔ Pfizer ✔ Pfizer ✔ Baxter

100 mg OP ✔ Baxter

161

MYCOPHENOLATE MOFETIL – Special Authority see SA1041 – Retail pharmacy ( subsidy) Dispensing pharmacy should check which brand to dispense with the prescriber if prescribed generically. Tab 500 mg ........................................................................... 25.00 50 ✔ Cellcept Cap 250 mg ........................................................................... 25.00 100 ✔ Cellcept

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

37


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to General Rules

Effective 1 December 2013

Section A: General Rules 5.2 Practitioner’s Supply Orders The following provisions apply to the supply of Community Pharmaceuticals to Practitioners under a Practitioner’s Supply Order: 5.2.1 Subject to clause 5.2.3 and 5.2.6, a Practitioner may only order under a Practitioner’s Supply Order those Community Pharmaceuticals listed in Section E Part I and only in such quantities as set out in Section E Part I that the Practitioner requires to ensure medical supplies are available for emergency use, teaching and demonstration purposes, and for provision to certain patient groups where individual prescription is not practicable. 5.2.2 Any order for a Class B Controlled Drug or for buprenorphine hydrochloride must be written on a Special Practitioner’s Supply Order Controlled Drug Form supplied by the Ministry of Health. 5.2.3 A Practitioner may order such Community Pharmaceuticals as he or she expects to be required for personal administration to patients under the Practitioner’s care if: a) the Practitioner’s normal practice is in the specified areas listed in Section E Part II of the Schedule, or if the Practitioner is a locum for a Practitioner whose normal practice is in such an area. b) the quantities ordered are reasonable for up to one Month’s supply under the conditions normally existing in the practice. (The Practitioner may be called on by the Ministry of Health to justify the amounts of Community Pharmaceuticals ordered.) 5.2.4 No Community Pharmaceutical ordered under a Practitioner’s Supply order will be eligible for Subsidy unless: a) the Practitioner’s Supply Order is made on a form supplied for that purpose by the Ministry of Health, or approved by the Ministry of Health and which: i) is personally signed and dated by the Practitioner; and ii) sets out the Practitioner’s address; and iii) sets out the Community Pharmaceuticals and quantities, and; b) all the requirements of Sections B and C of the Schedule applicable to that pharmaceutical are met. 5.2.5 The Ministry of Health may, at any time, on the recommendation of an Advisory Committee appointed by the Ministry of Health for that purpose, by public notification, declare that a Practitioner specified in such a notice is not entitled to obtain supplies of Community Pharmaceuticals under Practitioner’s Supply Orders until such time as the Ministry of Health notifies otherwise. 5.2.6 A Practitioner working in the Rheumatic Fever Prevention Programme (RFPP) may order under a Practitioner’s Supply Order such Community Pharmaceuticals (identified below) as he or she requires to ensure medical supplies are available for patients with suspected or confirmed Group A Streptococcal throat infections for the purposes of the RFPP in the following circumstances: a) the RFPP provider name is written on the Practitioner’s Supply Order; and b) the total quantity ordered does not exceed a multiple of: i) ten times the Practitioner’s Supply Order current maximum listed in Section E Part I for amoxycillin grans for oral liq 250 mg per 5 ml, amoxycillin cap 250 mg and amoxycillin cap 500 mg; or ii) two times the Practitioner’s Supply Order current maximum listed in Section E Part I for phenoxymethyl penicillin grans for oral liquid 250 mg per 5 ml, phenoxymethyl penicillin cap 500 mg, erythromycin ethyl succinate grans for oral liq 200 mg per 5 ml and erythromycin ethyl succinate tab 400 mg; and c) the practitioner must specify the order quantity in course-specific amounts on the Practitioner’s Supply Order (e.g. 10 x 300 ml amoxycillin grans for oral liq 250 mg per 5 ml). This will enable the pharmacy to dispense each course separately and claim multiple service fees as per the Community Pharmacy Services Agreement.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

38

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to General Rules - effective 1 November 2013

14 “Pharmaceutical” means a medicine, therapeutic medical device, or related product or related thing listed in Sections B to I H of the Schedule.

Effective 1 September 2013

15 “Specialist”, in relation to a Prescription, means a doctor who holds a current annual practising certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) or (d) below: a) i) the doctor is vocationally registered in accordance with the criteria set out by the Medical Council of New Zealand and the HPCA Act 2003 and who has written the prescription in the course of practising in that area of medicine; and or ii) the doctor’s vocational scope of practice is one of those listed below: — anaesthetics, cardiothoracic surgery, dermatology, diagnostic radiology, emergency medicine, general surgery, internal medicine, neurosurgery, obstetrics and gynaecology, occupational medicine, ophthalmology, oral and maxillofacial surgery, otolaryngology head and neck surgery, orthopaedic surgery, paediatric surgery, paediatrics, pathology, plastic and reconstructive surgery, psychological medicine or psychiatry, public health medicine, radiation oncology, rehabilitation medicine, urology and venereology; or b) the doctor is recognised by the Ministry of Health as a specialist for the purposes of this Schedule and receives remuneration from a DHB at a level which that DHB considers appropriate for specialists and who has written that prescription in the course of practising in that area of medicine; or c) the doctor is recognised by the Ministry of Health as a specialist in relation to a particular area of medicine for the purpose of writing Prescriptions and who has written the Prescription in the course of practising in that area of medicine; or d) the doctor writes the prescription on DHB stationery and is appropriately authorised by the relevant DHB to do so. 3.3 Original Packs, Certain Antibiotics and Unapproved Medicines 3.3.1 Notwithstanding clauses 3.1 and 3.3 of the Schedule, if a Practitioner prescribes or orders a Community Pharmaceutical that is identified as an Original Pack (OP) on the Pharmaceutical Schedule and is packed in a container from which it is not practicable to dispense lesser amounts, every reference in those clauses to an amount or quantity eligible for Subsidy, is deemed to be a reference: a) where an amount by weight or volume of the Community Pharmaceutical is specified in the Prescription, to the smallest container of the Community Pharmaceutical, or the smallest number of containers of the Community Pharmaceutical, sufficient to provide that amount; and b) in every other case, to the amount contained in the smallest container of the Community Pharmaceutical that is manufactured in, or imported into, New Zealand. 3.3.2 If a Community Pharmaceutical is either: a) the liquid oral form of an antibiotic to which a diluent must be added by the Contractor at the time of dispensing; or b) an unapproved medicine supplied under Section 29 of the Medicines Act 1981, but excluding any medicine listed as Cost, Brand, Source of Supply,or c) any other pharmaceutical that PHARMAC determines, from time to time and notes in the Pharmaceutical Schedule. and it is prescribed or ordered by a Practitioner in an amount that does not coincide with the amount contained in one or more standard packs of that Community Pharmaceutical, Subsidy will be paid for the amount prescribed or ordered by the Practitioner in accordance with either clause 3.1 or clause 3.3 of the Schedule, and for the balance of any pack or packs from which the Community Pharmaceutical has been dispensed. At the time of dispensing the Contractor must keep a record of the quantity discarded. To ensure wastage is reduced, the Contractor should reduce the amount dispensed to make it equal to the quantity contained in a whole pack where: continued...

18

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

39


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to General Rules - effective 1 September 2013 (continued)

continued... a) the difference between the amount dispensed and the amount prescribed by the Practitioner is less than 10% (eg; if a prescription is for 105 mls then a 100ml pack would be dispensed); and b) in the reasonable opinion of the Contractor the difference would not affect the efficacy of the course of treatment prescribed by the Practitioner. Note: For the purposes of audit and compliance it is an act of fraud to claim wastage and then use the wastage amount for any subsequent prescription.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

40

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Brand Name

Effective 1 December 2013

43 43 48 CALCIUM GLUCONATE ❋ Inj 10%, 10 ml ......................................................................... 21.40 MAGNESIUM SULPHATE ❋ Inj 2 mmol per ml, 5 ml ........................................................... 26.60 HEPARIN SODIUM Inj 1,000 iu per ml, 5 ml ......................................................... 13.36 66.80 Inj 1,000 iu per ml, 35 ml ....................................................... 16.00 Inj 5,000 iu per ml, 1 ml ......................................................... 14.20 Inj 25,000 iu per ml, 0.2 ml ....................................................... 9.50 ADRENALINE Inj 1 in 1,000, 1 ml ampoule – Up to 5 inj available on a PSO ..... 5.25 Inj 1 in 10,000, 10 ml ampoule – Up to 5 inj available on a PSO ........................................... 27.00 PAPAVERINE HYDROCHLORIDE ❋ Inj 12 mg per ml, 10 ml ampoule ............................................. 73.12 10 10 10 50 1 5 5 5 5 5 ✔ Hospira Mayne ✔ Hospira Mayne ✔ Hospira Mayne ✔ Hospira Mayne ✔ Hospira Mayne ✔ Hospira Mayne ✔ Hospira Mayne ✔ Hospira Mayne ✔ Hospira Mayne ✔ Hospira Mayne

61

62 92

GENTAMICIN SULPHATE Inj 10 mg per ml, 1 ml – Subsidy by endorsement ..................... 8.56 5 ✔ Hospira Mayne Only if prescribed for a dialysis or cystic fibrosis patient or complicated urinary tract infection and the prescription is endorsed accordingly. DIAZEPAM – Safety medicine; prescriber may determine dispensing frequency Inj 5 mg per ml, 2 ml – Subsidy by endorsement ....................... 9.24 5 a) Up to 5 inj available on a PSO b) Only on a PSO c) PSO must be endorsed “not for anaesthetic procedures”. PHENYTOIN SODIUM ❋ Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO ............ 69.24 ❋ Inj 50 mg per ml, 5 ml – Up to 5 inj available on a PSO ............ 77.27 HYOSCINE HYDROBROMIDE ❋ Inj 400 mcg per ml, 1 ml ........................................................... 6.66 CISPLATIN – PCT only – Specialist Inj 1 mg per ml, 50 ml ............................................................. 15.00 Inj 1 mg per ml, 100 ml .......................................................... 21.00 CALCIUM FOLINATE Inj 3 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist ........ 17.10 5 5 5 1 1 5 ✔ Hospira Mayne

126

126 131 147

✔ Hospira Mayne ✔ Hospira Mayne ✔ Hospira Mayne ✔ Hospira DBL Cisplatin ✔ Hospira DBL Cisplatin ✔ Hospira Mayne

148

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

41


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Brand Name - effective 1 December 2013 (continued)

148 CYTARABINE Inj 20 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist ................................................ 80.00 Inj 500 mg – PCT – Retail pharmacy-Specialist ........................ 95.36 Inj 100 mg per ml, 10 ml vial – PCT – Retail pharmacy-Specialist ................................................ 42.65 Inj 100 mg per ml, 20 ml vial – PCT – Retail pharmacy-Specialist ................................................ 34.47 FLUOROURACIL SODIUM Inj 25 mg per ml, 100 ml – PCT only – Specialist ..................... 13.55 METHOTREXATE ❋ Inj 2.5 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist ..... 23.65 ETOPOSIDE Inj 20 mg per ml, 5 ml – PCT – Retail pharmacy-Specialist ................................................ 25.00 VINBLASTINE SULPHATE Inj 10 mg – PCT – Retail pharmacy-Specialist .......................... 27.50 137.50 PROMETHAZINE HYDROCHLORIDE ❋ Inj 25 mg per ml, 2 ml – Up to 5 inj available on a PSO ............ 11.00 DESFERRIOXAMINE MESYLATE ❋ Inj 500 mg ............................................................................. 99.00 NALOXONE HYDROCHLORIDE a) Up to 5 inj available on a PSO b) Only on a PSO ❋ Inj 400 mcg per ml, 1 ml ......................................................... 33.00

5 5 5 1 1 5

✔ Hospira Mayne ✔ Hospira Mayne ✔ Hospira Mayne ✔ Hospira Mayne ✔ Hospira Mayne ✔ Hospira Mayne

149 149 151

1 1 5 5 10

✔ Hospira Mayne ✔ Hospira Mayne ✔ Hospira Mayne ✔ Hospira Mayne ✔ Hospira Mayne

154

177 187 187

5

✔ Hospira Mayne

Effective 1 November 2013

116 BENZBROMARONE – Special Authority see SA1319 – Retail pharmacy Tab 100 mg ............................................................................ 45.00 100 ✔ Benzbromaron Benzbromaron AL 100 S29 ✔ Madopar Dispersible Madopar Rapid

118

LEVODOPA WITH BENSERAZIDE ❋ Tab dispersible 50 mg with benserazide 12.5 mg ..................... 10.00

100

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

42

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Section I

Effective 1 October 2013

225 HEPATITIS A VACCINE – Hospital pharmacy [Xpharm] Children, aged 1–4 years inclusive who reside in Ashburton district; or Children, aged 1–9 years inclusive, residing in Ashburton; or Children, aged 1–9 years inclusive, who attend a preschool or school in Ashburton; or Children, aged older than 9 years, who attend a school with children aged 9 years old or less, in Ashburton Inj ............................................................................................. 0.00 1 ✔ Havrix Junior

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

43


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items

Effective 1 December 2013

32 39 INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE – Maximum of 100 dev per prescription ❋ Syringe 0.3 ml with 31 g × 8 mm needle ................................ 13.00 100 ✔ ABM MACROGOL 3350 – Special Authority see SA0891 – Retail pharmacy Powder 13.125 g, sachets – Maximum of 60 sach per prescription ............................... 18.14 CONDOMS ❋ 53 mm extra strength – Up to 144 dev available on a PSO ....................................... 1.11 13.36 PHARMACY SERVICES Brand switch fee ....................................................................... 4.33 METHYLCELLULOSE Powder ................................................................................... 14.00

30

✔ Movicol

75

12 144 1 fee 100 g

✔ Gold Knight ✔ Gold Knight ✔ BSF Acetec ✔ ABM

187 194

Effective 1 November 2013

181 212 SODIUM CROMOGLYCATE Nasal spray, 4% ..................................................................... 15.85 22 ml OP ✔ Rex

AMINOACID FORMULA WITHOUT PHENYLALANINE – Special Authority see SA1108 – Hospital pharmacy [HP3] Sachets (tropical) .................................................................. 324.00 30 ✔ Phlexy 10

Effective 1 October 2013

46 58 65 SODIUM TETRADECYL SULPHATE ❋ Inj 0.5% 2 ml .......................................................................... 23.20 (51.00) ❋ Inj 1% 2 ml ............................................................................. 25.00 (55.00) CLONIDINE HYDROCHLORIDE ❋ Tab 25 mcg............................................................................. 13.47 CICLOPIROX OLAMINE a) Only on a prescription b) Not in combination Nail soln 8% ........................................................................... 19.85 LEVONORGESTREL ❋ Tab 750 mcg ............................................................................ 3.50 5 Fibro-vein 5 Fibro-vein 100 ✔ Dixarit

3 g OP 2

✔ Batrafen ✔ Next Choice

78

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

44

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items - effective 1 October 2013 (continued)

76 ETHINYLOESTRADIOL WITH DESOGESTREL ❋ Tab 20 mcg with desogestrel 150 mcg ..................................... 6.62 (16.50) a) Higher subsidy of $13.80 per 63 tab with Special Authority see SA0500 b) Up to 63 tab available on a PSO ❋ Tab 30 mcg with desogestrel 150 mcg ..................................... 6.62 (16.50) a) Higher subsidy of $13.80 per 63 tab with Special Authority see SA0500 b) Up to 63 tab available on a PSO 63 Mercilon 21 63 Marvelon 21

88

CEFOXITIN SODIUM – Retail pharmacy-Specialist – Subsidy by endorsement Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly. Inj 1 g .................................................................................... 55.00 5 ✔ Mayne CEFUROXIME SODIUM Inj 250 mg – Maximum of 3 inj per prescription; can be waived by endorsement ....................................................... 20.97 10 ✔ Mayne Waiver by endorsement must state that the prescription is for dialysis or cystic fibrosis patient. Inj 1.5 g – Retail pharmacy-Specialist – Subsidy by endorsement .................................................... 2.65 1 ✔ Mylan 4.04 ✔ Zinacef Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly. FUSIDIC ACID Inj 500 mg sodium fusidate per 10 ml – Retail pharmacySpecialist – Subsidy by endorsement ................................... 12.87 1 (17.80) Fucidin Only if prescribed for a dialysis or cystic fibrosis patient and the prescription is endorsed accordingly. LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE Inj 2%, 5 ml ampoule – Up to 5 inj available on a PSO .............. 13.80 Inj 2%, 20 ml ampoule – Up to 5 inj available on a PSO ............ 12.00 50 5 ✔ Xylocaine ✔ Xylocaine

88

92

119

130

SUMATRIPTAN Tab 50 mg ............................................................................... 1.19 4 ✔ Arrow-Sumatriptan Tab 100 mg ............................................................................. 1.10 4 ✔ Arrow-Sumatriptan Note – Arrow-Sumatriptan tab 50 mg and 100 mg in 100 tab pack size remains subsidised. HOMATROPINE HYDROBROMIDE ❋ Eye drops 2% ........................................................................... 7.18 PHARMACY SERVICES ❋ Brand switch fee ....................................................................... 4.33 15 ml OP 1 fee ✔ Isopto Homatropine ✔ BSF Arrow-Quinapril

185 187

Effective 1 September 2013

31 INSULIN PEN NEEDLES – Maximum of 100 dev per prescription ❋ 29 g × 12.7 mm ..................................................................... 10.50 100 ✔ ABM

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

45


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items - effective 1 September 2013 (continued)

32 107 INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE – Maximum of 100 dev per prescription ❋ Syringe 0.3 ml with 29 g × 12.7 mm needle ........................... 13.00 100 ✔ ABM ❋ Syringe 0.5 ml with 29 g × 12.7 mm needle ........................... 13.00 100 ✔ ABM ❋ Syringe 0.5 ml with 31 g × 8 mm needle ................................ 13.00 100 ✔ ABM PEGYLATED INTERFERON ALFA-2A – Special Authority see SA1365 – Retail pharmacy See prescribing guideline Inj 135 mcg prefilled syringe .................................................. 362.00 1 ✔ Pegasys Inj 180 mcg prefilled syringe ................................................. 450.00 1 ✔ Pegasys FAT SUPPLEMENT – Special Authority see SA1374 – Hospital pharmacy [HP3] Oil ........................................................................................... 28.73 250 ml OP ✔ Liquigen ENTERAL FEED 1KCAL/ML – Special Authority see SA1228 – Hospital pharmacy [HP3] Liquid ........................................................................................ 2.65 500 ml OP ✔ Nutrison Standard RTH ENTERAL FEED WITH FIBRE 1 KCAL/ML – Special Authority see SA1228 – Hospital pharmacy [HP3] Liquid ........................................................................................ 2.65 500 ml OP ✔ Nutrison Multi Fibre

199 207

207

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

46

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted

Effective 1 January 2014

59 CHLORTALIDONE [CHLORTHALIDONE] ❋ Tab 25 mg ................................................................................ 4.80 30 Note – The delist date has been extended from 1 October 2013 to 1 January 2014. OXYCODONE HYDROCHLORIDE a) Only on a controlled drug form b) See prescribing guideline c No patient co-payment payable d) Safety medicine; prescriber may determine dispensing frequency Tab controlled-release 10 mg .................................................... 6.75 (11.14) Tab controlled-release 20 mg ................................................. 11.50 (18.93) Tab controlled-release 40 mg ................................................. 18.50 (33.29) Tab controlled-release 80 mg .................................................. 34.00 (58.03) INFLUENZA VACCINE – Hospital pharmacy [Xpharm] Inj .......................................................................................... 90.00 ✔ Igroton S29

122

20 20 20 20

OxyContin OxyContin OxyContin OxyContin

225

10

✔ Fluvax

Effective 1 February 2014

161 MYCOPHENOLATE MOFETIL – Special Authority see SA1041 – Retail pharmacy Dispensing pharmacy should check which brand to dispense with the prescriber if prescribed generically. Tab 500 mg ............................................................................ 25.00 50 ✔ Myaccord (60.00) Ceptolate Cap 250 mg ............................................................................ 12.50 (30.00) 25.00 50 100 Ceptolate ✔ Myaccord

Effective 1 March 2014

46 CLOPIDOGREL ❋ Tab 75 mg – For clopidogrel oral liquid formulation refer, page 189 ............................................................................... 5.87 (16.25) NORETHISTERONE WITH MESTRANOL ❋ Tab 1 mg with mestranol 50 mcg and 7 inert tab........................ 6.62 (13.80) a) Higher subsidy of $13.80 per 84 tab with Special Authority see SA0500 b) Up to 84 tab available on a PSO

90 Apo-Clopidogrel 84 Norinyl-1/28

77

79

TAMSULOSIN HYDROCHLORIDE – Special Authority see SA1032 – Retail pharmacy ❋ Cap 400 mcg ........................................................................... 4.05 30 (5.98)

Tamsulosin-Rex

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

47


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted - effective 1 March 2014 (continued)

90 131 161 176 PENICILLIN G BENZATHINE [BENZATHINE BENZYLPENICILLIN] Inj 1.2 mega u per 2 ml – Up to 5 inj available on a PSO......... 315.00 ONDANSETRON ❋ Tab disp 4 mg ......................................................................... 17.18 AZATHIOPRINE – Retail pharmacy-Specialist ❋ Tab 50 mg – For azathioprine oral liquid formulation refer, page 189 ............................................................................. 18.45 LORATADINE ❋ Tab 10 mg ................................................................................ 1.30 (2.09) PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN ❋ Eye oint with soft white paraffin ................................................. 3.63 10 10 ✔ Bicillin LA ✔ Zofran Zydis

100 100

✔ Imuran

Loraclear Hayfever Relief 3.5 g OP ✔ Lacri-Lube

186 202

PAEDIATRIC ORAL FEED 1KCAL/ML – Special Authority see SA1379 – Hospital pharmacy [HP3] Liquid (chocolate) .................................................................... 1.07 200 ml OP ✔ Pediasure Liquid (strawberry) ................................................................... 1.07 200 ml OP ✔ Pediasure Liquid (vanilla) .......................................................................... 1.07 200 ml OP ✔ Pediasure 1.27 237 ml OP ✔ Pediasure Note – Replacement Pediasure packs were listed 1 September 2013.

Effective 1 April 2014

131 ONDANSETRON ❋ Tab disp 4 mg .......................................................................... 0.68 ✔ Dr Reddy’s Ondansetron Note – Dr Reddy's Ondansetron tab dispersible 4 mg in the 100 pack size remains subsidised. CYCLOPHOSPHAMIDE Tab 50 mg – PCT – Retail pharmacy-Specialist........................ 25.71 BUDESONIDE Powder for inhalation, 200 mcg per dose ................................ 15.20 Powder for inhalation, 400 mcg per dose ................................ 25.60 50 ✔ Cycloblastin 4

147 177

200 dose OP ✔ Budenocort 200 dose OP ✔ Budenocort

Effective 1 May 2014

52 ENALAPRIL MALEATE ❋ Tab 5 mg .................................................................................. 1.07 ❋ Tab 10 mg ............................................................................... 1.32 ❋ Tab 20 mg – For enalapril maleate oral liquid formulation refer, page 189................................................................................... 1.72 90 90 90 ✔ m-Enalapril ✔ m-Enalapril ✔ m-Enalapril

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

48

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted - effective 1 May 2014 (continued)

86 LEVOTHYROXINE ❋ Tab 25 mcg ............................................................................ 43.24 1,000 ‡ Safety cap for extemporaneously compounded oral liquid preparations. ❋ Tab 50 mcg ............................................................................ 45.00 1,000 ‡ Safety cap for extemporaneously compounded oral liquid preparations. Note – Synthroid in the 90 tablet pack size remain subsidised. METHOTREXATE ❋ Inj 25 mg per ml, 40 ml – PCT – Retail pharmacy - Specialist ............................................. 25.00 ✔ Synthroid ✔ Synthroid

149

1

✔ DBL Methotrexate

S29

207

ORAL FEED (POWDER) – Special Authority see SA1228 – Hospital pharmacy [HP3] Powder (vanilla) ..................................................................... 13.00 900 g OP

✔ Ensure

Effective 1 June 2014

31 105 INSULIN PEN NEEDLES – Maximum of 100 dev per prescription ❋ 31 g × 6 mm ......................................................................... 10.50 (26.00) 100 NovoFine

ZIDOVUDINE [AZT] WITH LAMIVUDINE – Special Authority see SA1364 – Retail pharmacy Note: zidovudine [AZT] with lamivudine (combination tablets) counts as two anti-retroviral medications for the purposes of the anti-retroviral Special Authority. Tab 300 mg with lamivudine 150 mg ..................................... 667.20 60 ✔ Combivir CARBOHYDRATE SUPPLEMENT – Special Authority see SA1373 – Hospital pharmacy [HP3] Powder ..................................................................................... 1.30 368 g OP (12.00) Moducal

197

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

49


Index

Pharmaceuticals and brands Symbols 3TC ................................................................... 36 A Acetec ............................................. 25, 26, 30, 31 Aclasta .............................................................. 31 Advate ............................................................... 20 Adrenaline.......................................................... 41 Alphamox .......................................................... 26 Alprazolam ................................................... 22, 35 Aminoacid formula without phenylalanine ........... 44 Amoxycillin ........................................................ 26 Apo-Clopidogrel ........................................... 35, 47 Apo-Perindopril .................................................. 31 Apo-Pindolol ...................................................... 36 Apo-Ropinirole ............................................. 21, 27 Apresoline s29 ............................................. 22, 29 Arrow-Alprazolam .............................................. 35 Arrow - Clopid.................................................... 22 Arrow-Gabapentin .............................................. 21 Arrow-Sumatriptan ............................................. 45 Arrow-Venlafaxine XR................................... 34, 37 Ascorbic acid ..................................................... 36 Azathioprine ....................................................... 48 B Batrafen ............................................................. 44 BeneFIX ............................................................. 20 Benzbromaron ................................................... 42 Benzbromaron AL 100 ....................................... 42 Benzbromaron AL100 ........................................ 27 Benzbromarone ............................................ 27, 42 Bicillin LA........................................................... 48 Boceprevir ......................................................... 24 Bplex ................................................................. 36 B-PlexADE ......................................................... 36 BSF Acetec .................................................. 25, 44 BSF Arrow-Quinapril ........................................... 45 Budenocort ........................................................ 48 Budesonide ........................................................ 48 C Calcium folinate ................................................. 41 Calcium gluconate ............................................. 41 Carbimazole ....................................................... 26 Carbohydrate supplement................................... 49 Cefaclor monohydrate ........................................ 35 Cefoxitin sodium ................................................ 45 Cefuroxime sodium ............................................ 45 Cellcept ............................................................. 37 Ceptolate ..................................................... 35, 47 Cetomacrogol with glycerol .......................... 22, 26 Chlortalidone [chlorthalidone] ............................. 47 Ciclopirox olamine.............................................. 44 Cilicaine VK........................................................ 27 Cisplatin............................................................. 41 Clomazol............................................................ 35 Clonidine hydrochloride ...................................... 44 Clopidogrel ............................................ 22, 35, 47 Clotrimazole ....................................................... 35 Combivir ............................................................ 49 Condoms ........................................................... 44 Compound electrolytes................................. 21, 26 Coversyl ............................................................ 31 Cvite .................................................................. 36 Cycloblastin ....................................................... 48 Cyclophosphamide ...................................... 23, 48 Cytarabine ............................................. 34, 37, 42 D DBL Methotrexate............................................... 49 Dr Reddy’s Ondansetron .................................... 48 Desferrioxamine mesylate .................................. 42 Desmopressin .................................................... 24 Dextrose with electrolytes................................... 36 Dixarit ................................................................ 44 E Efexor XR ........................................................... 34 Electral .............................................................. 26 E-Mycin ............................................................. 26 Efexor XR ........................................................... 34 Enalapril maleate .................. 22, 25, 26, 30, 31, 48 Enerlyte ....................................................... 21, 26 Ensure ......................................................... 22, 49 Enteral feed 1kcal/ml .......................................... 46 Enteral feed with fibre 1 kcal/ml .......................... 46 Eptacog alfa [recombinant factor viia]................. 20 Erythromycin ethyl succinate .............................. 26 Ethics Enalapril ............................................ 22, 30 Ethinyloestradiol with desogestrel ....................... 45 Etoposide........................................................... 42 F Factor eight inhibitors bypassing agent ............... 20 Fat supplement .................................................. 46 FEIBA................................................................. 20 Fibro-vein........................................................... 44 Fluorouracil sodium............................................ 42 Fluvax ................................................................ 47 Fucidin ............................................................... 45 Fusidic acid........................................................ 45 G Gabapentin ........................................................ 21 Gemfibrozil ........................................................ 36 Genox ................................................................ 23 Gentamicin sulphate ........................................... 41 Glivec ................................................................ 28

50


Index

Pharmaceuticals and brands Gold Knight ........................................................ 44 H Havrix Junior ...................................................... 43 healthE Urea Cream............................................ 21 Heparin sodium.................................................. 41 Hepatitis A vaccine............................................. 43 Homatropine hydrobromide ................................ 45 Hydralazine hydrochloride ............................ 22, 29 Hyoscine (scopolamine)..................................... 31 Hyoscine hydrobromide ............................... 31, 41 I Igroton ............................................................... 47 Imatinib mesilate ................................................ 28 Imuran ............................................................... 48 Influenza vaccine................................................ 47 Insulin pen needles....................................... 45, 49 Insulin syringes, disposable with attached needle ................................. 44, 46 Interferon alfa-2a................................................ 32 Interferon alfa-2b ............................................... 32 Interferon alpha-2a ............................................. 32 interferon alpha-2b ............................................. 32 Imatinib mesylate ............................................... 28 Imipramine hydrochloride ............................. 25, 30 Intron-A ............................................................. 32 Isopto Homatropine ............................................ 45 K Kogenate FS....................................................... 20 L Lacri-Lube ......................................................... 48 Lactulose ........................................................... 21 Laevolac ............................................................ 21 Lamivudine .................................................. 21, 36 Lamivudine Alphapharm ..................................... 21 Levodopa with benserazide ................................ 42 Levonorgestrel ................................................... 44 Levothyroxine .................................................... 49 Lidocaine [lignocaine] hydrochloride ............ 37, 45 Lipazil ................................................................ 36 Liquigen ............................................................. 46 Lorafix ............................................................... 23 Loraclear Hayfever Relief.............................. 35, 48 Loratadine.............................................. 23, 35, 48 Loxamine ........................................................... 22 Ludiomil s29 ...................................................... 23 M Macrogol 3350 .................................................. 44 Madopar Dispersible .......................................... 42 Madopar Rapid .................................................. 42 Magnesium sulphate .......................................... 41 Maprotiline hydrochloride ............................. 23, 30 Marvelon 21....................................................... 45 m-Enalapril ............................................ 30, 31, 48 Mercilon 21 ....................................................... 45 Mesalazine ................................................... 20, 23 m-Eslon ............................................................. 35 Methotrexate Sandoz .......................................... 22 Methylcellulose .................................................. 44 Methotrexate .......................................... 22, 42, 49 Minirin ............................................................... 24 Moducal ............................................................ 49 Montelukast ....................................................... 28 Moroctocog alfa [recombinant factor viii] ........... 20 Morphine sulphate.............................................. 35 Movicol.............................................................. 44 MultiADE............................................................ 36 Mvite ................................................................. 36 Myaccord .................................................... 35, 47 Mycophenolate mofetil ........................... 35, 37, 47 N Naloxone hydrochloride ...................................... 42 Naltraccord ........................................................ 28 Naltrexone hydrochloride .................................... 28 Neo-Mercazole ................................................... 26 NeuroKare.......................................................... 36 Next Choice ....................................................... 44 Nonacog alfa [recombinant factor ix] .................. 20 Norethisterone with mestranol ............................ 47 Norinyl-1/28 ...................................................... 47 NovoFine ........................................................... 49 NovoSeven RT ................................................... 20 Nutrini Low Energy Multi Fibre ............................ 34 Nutrison Multi Fibre ............................................ 46 Nutrison Standard RTH....................................... 46 O Octocog alfa [recombinant factor viii] ................. 20 Olanzapine ......................................................... 21 Ondansetron ................................................ 22, 48 Onrex ................................................................. 22 Oral feed (powder) ....................................... 22, 49 Ospamox ........................................................... 26 Oxycodone hydrochloride ....................... 31, 36, 47 OxyContin .................................................... 36, 47 OxyNorm ........................................................... 31 Oxytocin ...................................................... 21, 26 Oxytocin BNM .............................................. 21, 26 P Paediatric enteral feed with fibre 0.75 Kcal/ml..... 34 Paediatric enteral feed with fibre 0.76 kcal/ml ..... 34 Paediatric oral feed 1kcal/ml......................... 25, 48 Papaverine hydrochloride ................................... 41 Paraffin liquid with soft white paraffin ........... 25, 48

51


Index

Pharmaceuticals and brands Paroxetine hydrochloride .................................... 22 Pedialyte – Bubblegum ....................................... 36 Pediasure..................................................... 25, 48 Pegasys............................................................. 32 Pegasys................................................. 32, 37, 46 Pegasys RBV Combination Pack .................. 32, 37 Pegylated interferon alfa-2a .................... 32, 37, 46 Pegylated interferon alpha-2a ............................. 32 Penicillin g benzathine [benzathine benzylpenicillin] ............................ 48 Pentasa ....................................................... 20, 23 Perindopril ......................................................... 31 Pharmacy Health Sorbolene with Glycerin ..... 22, 26 Pharmacy services................................. 25, 44, 45 Phenoxymethylpenicillin (penicillin v) .................. 27 Phenytoin sodium .............................................. 41 Phlexy 10........................................................... 44 Pindolol ............................................................. 36 Potassium iodate ............................................... 36 Pramipexole hydrochloride ................................. 21 Procytox ............................................................ 23 Promethazine hydrochloride ............................... 42 R Ramipex ............................................................ 21 Ranbaxy-Cefaclor............................................... 35 Refresh Night Time ............................................ 25 Rilutek ............................................................... 23 Riluzole .............................................................. 23 Risedronate Sandoz ........................................... 24 Risedronate sodium ........................................... 24 Risperdal Quicklet .............................................. 34 Risperidone........................................................ 34 Roferon-A .......................................................... 32 Ropin ................................................................. 27 Ropinirole hydrochloride............................... 21, 27 S Salapin .............................................................. 30 Salbutamol................................................... 22, 30 Scopoderm TTS ................................................. 31 Singulair ............................................................ 28 Sodium cromoglycate ........................................ 44 Sodium tetradecyl sulphate ................................ 44 Spiractin ............................................................ 21 Spironolactone ................................................... 21 Sumatriptan ....................................................... 45 Synacthen.................................................... 23, 31 Synthroid ........................................................... 49 Syntocinon......................................................... 26 T Tamoxifen citrate................................................ 23 Tamsulosin hydrochloride ...................... 22, 35, 47 Tamsulosin-Rex ..................................... 22, 35, 47 Tepadina ............................................................ 25 Tetracosactrin .............................................. 23, 31 Thiotepa............................................................. 25 Tofranil s29 ....................................................... 30 Tofranil S29 ....................................................... 25 U Urea................................................................... 21 V Valcyte............................................................... 29 Valganciclovir .................................................... 29 Venlafaxine .................................................. 34, 37 Ventolin ....................................................... 22, 30 Victrelis.............................................................. 24 Vinblastine sulphate ........................................... 42 Vitala-C .............................................................. 36 Vitamin B complex ............................................. 36 Vitamins ............................................................ 36 X Xanax................................................................. 22 Xylocaine ..................................................... 37, 45 Xyntha ............................................................... 20 Z Zidovudine [azt] with lamivudine ......................... 49 Zofran Zydis ....................................................... 48 Zoledronic acid .................................................. 31 Zypine................................................................ 21 Zypine ODT ........................................................ 21

52


Pharmaceutical Management Agency Level 9, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz Freephone Information line (9am-5pm weekdays) 0800 66 00 50 ISSN 1172-9376 (Print) ISSN 1179-3686 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

If Undelivered, Return To: PO Box 10-254, Wellington 6143, New Zealand

Metadata

Title

Schedule Update - effective 1 December 2013

Abstract

Pharmaceutical Management Agency Section H for Hospital Pharmaceuticals The Hospital Medicines List (HML) Update Update Effective 1 December 2013 New Zealand Cumulative for November and December 2013 Pharmaceutical Schedule Effective 1 July 2013 Cumulative for May, June and July 2013…

Page 1

icon

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.